https://trial.medpath.com/news/otsuka-pharmaceutical-secures-exclusive-rights-to-sky-labs-cuffless-blood-pressure-monitor-for-japan-market 2026-02-06T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaresearch-receives-fda-clearance-for-phase-1-trial-of-nano-anticancer-drug-prd-101 2026-02-06T09:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-phase-2-trial-of-mibavademab-for-functional-hypothalamic-amenorrhea 2026-02-06T09:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-reports-progress-across-rna-therapy-pipeline-with-strong-financial-position 2026-02-06T09:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-approves-velsipity-for-moderately-to-severely-active-ulcerative-colitis 2026-02-06T09:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-reports-strong-q2-2025-performance-with-pipeline-advances-and-raised-guidance 2026-02-06T05:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/iit-bombay-develops-gentler-t-cell-recovery-method-to-enhance-car-t-cell-therapy-efficiency 2026-02-06T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/fagron-expands-global-pharmaceutical-compounding-network-with-strategic-acquisitions-in-brazil-and-hungary 2026-02-06T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-reports-six-year-data-showing-tralesinidase-alfa-preserves-cognitive-function-in-sanfilippo-syndrome-type-b 2026-02-06T01:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-amtagvi-achieves-44-response-rate-in-advanced-melanoma-exceeding-clinical-trial-results 2026-02-06T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/ixico-appoints-new-chief-commercial-officer-to-accelerate-neuroscience-imaging-business-growth 2026-02-06T01:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-genetic-testing-for-xeloda-and-5-fu-to-prevent-fatal-toxicities-in-dpd-deficient-patients 2026-02-06T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/abcuro-s-ulviprubart-misses-primary-endpoints-in-inclusion-body-myositis-trial-shows-promise-in-mild-to-moderate-patients 2026-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/urate-lowering-treatment-reduces-cardiovascular-risk-in-gout-patients-by-9 2026-02-05T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/adarx-pharmaceuticals-appoints-donald-fong-as-chief-medical-officer-to-lead-rna-therapeutics-pipeline 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-heart-drug-dronedarone-shows-promise-as-novel-lymphoma-treatment-through-usp11-enzyme-targeting 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/menstrual-blood-hpv-testing-achieves-comparable-accuracy-to-clinician-sampling-in-large-chinese-study 2026-02-05T21:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-implements-sweeping-policy-changes-to-accelerate-drug-approvals-and-transform-regulatory-landscape 2026-02-05T21:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-cdmo-alphora-partners-with-uk-company-to-develop-revolutionary-adc-manufacturing-platform 2026-02-05T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/infleqtion-advances-quantum-enabled-biomarker-discovery-for-precision-oncology-to-final-phase-of-wellcome-leap-challenge 2026-02-05T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vybrique-first-sildenafil-oral-film-for-erectile-dysfunction-treatment 2026-02-05T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/sonorous-neurovascular-receives-fda-breakthrough-device-designation-for-bosstent-to-treat-pulsatile-tinnitus 2026-02-05T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/crohn-s-disease-clinical-trials-show-promising-pipeline-with-novel-therapies-advancing-through-development 2026-02-05T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-analysis-reveals-global-phenylketonuria-clinical-trials-landscape-and-strategic-opportunities 2026-02-05T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/photonpharma-initiates-phase-1-trial-of-innocell-autologous-immunotherapy-for-recurrent-ovarian-cancer 2026-02-05T17:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-reduce-amputation-risk-and-cardiovascular-events-in-high-risk-diabetes-patients 2026-02-05T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/point-of-care-testing-for-hepatitis-b-dna-shows-high-accuracy-in-clinical-trial-expanding-access-to-diagnosis-and-treatment 2026-02-05T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-reports-positive-results-for-entyvio-biosimilar-in-pivotal-pharmacokinetic-study 2026-02-05T13:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/crest-2-trial-shows-carotid-revascularization-fails-to-improve-cognitive-function-in-asymptomatic-patients 2026-02-05T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-streamlines-oncology-pipeline-discontinues-six-phase-1-cancer-programs 2026-02-05T09:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-liverpool-partners-with-bpgbio-to-advance-ai-driven-drug-discovery-platform 2026-02-05T09:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/orthocell-advances-us-commercial-strategy-following-fda-approval-for-nerve-repair-device 2026-02-05T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-narrows-moderna-s-patent-defenses-in-8-2-billion-arbutus-lnp-technology-dispute 2026-02-05T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/jcr-pharmaceuticals-presents-promising-blood-brain-barrier-data-for-rare-disease-therapies-at-worldsymposium-2026 2026-02-05T05:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-endovascular-completes-spirare-ii-trial-enrollment-for-vertex-pulmonary-embolectomy-system 2026-02-05T00:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/sovateltide-shows-92-success-rate-in-phase-iv-stroke-trial-demonstrating-significant-functional-recovery 2026-02-05T00:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-ai-driven-analysis-confirms-vanoglipel-s-therapeutic-targets-for-mash-and-type-2-diabetes 2026-02-05T00:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/fastest-trial-shows-mixed-results-for-factor-viia-in-acute-intracerebral-hemorrhage-signals-promise-in-early-treatment-subgroups 2026-02-05T00:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-therapy-pipeline-expands-with-100-companies-developing-novel-cancer-treatments 2026-02-05T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/coeptis-therapeutics-advances-cell-therapy-pipeline-while-pursuing-strategic-merger-with-cryptocurrency-mining-company 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-next-generation-cardiomems-hero-reader-receives-fda-approval-for-heart-failure-monitoring 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-initiates-first-in-human-trial-of-ds3790-novel-cd37-targeted-adc-for-b-cell-lymphoma 2026-02-04T21:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-amphotericin-b-shows-comparable-efficacy-to-triazoles-in-invasive-aspergillosis-treatment 2026-02-04T21:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/qt-sense-secures-eur4m-to-advance-quantum-nanodiamond-platform-for-real-time-cellular-drug-discovery 2026-02-04T21:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/intra-arterial-alteplase-after-thrombectomy-shows-significant-improvement-in-stroke-recovery-outcomes 2026-02-04T20:58:24+00:00 hourly 0.9 https://trial.medpath.com/news/primegen-us-secures-1-5-billion-spac-merger-to-advance-triple-activated-stem-cell-platform-for-acute-liver-injury 2026-02-04T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-study-shows-trx103-cell-therapy-accelerates-immune-recovery-in-mismatched-stem-cell-transplants 2026-02-04T17:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-launches-first-immunotherapy-trial-for-colorectal-cancer-in-sub-saharan-africa 2026-02-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/third-arc-bio-raises-52-million-series-a-extension-to-advance-precision-immune-modulation-platform 2026-02-04T17:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-appoints-eugene-kennedy-as-chief-medical-advisor-following-early-clinical-success-with-wee1-inhibitor 2026-02-04T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/axon-neuroscience-s-aadvac1-selected-for-two-major-nih-funded-platform-trials-in-alzheimer-s-and-psp 2026-02-04T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-spatial-biology-analysis-reveals-new-insights-into-nsclc-immunotherapy-response 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biomedica-secures-five-year-commercial-supply-deal-with-bristol-myers-squibb-for-car-t-vector-manufacturing 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-receives-fda-clearance-to-begin-phase-1-2-trial-of-aftx-201-gene-therapy-for-rare-heart-disease 2026-02-04T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-initiates-first-in-human-trial-of-novel-beta-catenin-condensate-modulator-dptx3186 2026-02-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-faces-first-profit-decline-in-decade-as-key-drug-patents-expire 2026-02-04T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/aminex-therapeutics-initiates-phase-1b-2-trial-of-novel-polyamine-targeting-cancer-therapy-amxt-1501-plus-dfmo 2026-02-04T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/biodexa-secures-exclusive-license-for-novel-molecular-glue-mtx240-to-target-tki-resistant-gist 2026-02-04T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/addex-therapeutics-publishes-breakthrough-data-on-mglu7-targeting-for-anxiety-and-ptsd-treatment 2026-02-04T17:24:14+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-and-shanghai-lishan-biopharmaceuticals-announce-exclusive-global-licensing-deal-for-bmc128-microbiome-cancer-therapy 2026-02-04T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-to-present-final-phase-1b-results-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-02-04T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/hologic-s-aptima-hpv-assay-receives-fda-approval-for-primary-cervical-cancer-screening 2026-02-04T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2026-02-04T17:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-refuses-fda-request-to-withdraw-rare-disease-drug-tavneos-amid-data-integrity-concerns 2026-02-04T17:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/neomorph-begins-first-clinical-trial-of-molecular-glue-cancer-treatment-neo-811-for-kidney-cancer 2026-02-04T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-implements-major-clinical-trial-reform-with-mandatory-ivd-assessment-starting-april-2026 2026-02-04T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulatory-body-finds-sanofi-in-breach-over-unsubstantiated-rsv-therapy-claims-against-pfizer 2026-02-04T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/forus-health-receives-cdsco-approval-for-ai-powered-diabetic-retinopathy-screening-tool-in-india 2026-02-04T13:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/repotrectinib-demonstrates-durable-activity-in-ntrk-fusion-positive-solid-tumors-with-promising-outcomes-in-tki-pretreated-patients 2026-02-04T13:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-to-showcase-accum-r-intracellular-delivery-platform-at-world-adc-europe-2026 2026-02-04T13:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/cdr-life-appoints-dimitrios-chondros-as-chief-medical-officer-to-advance-t-cell-engager-platform 2026-02-04T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/major-cancer-research-coalition-launches-12-million-initiative-to-advance-early-detection-of-deadly-cancers 2026-02-04T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/cizzle-biotechnology-secures-canadian-patent-for-ciz1b-lung-cancer-biomarker-test 2026-02-04T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-identifies-inkt-cell-depletion-as-key-mechanism-in-advanced-idiopathic-pulmonary-fibrosis 2026-02-04T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-hiv-vaccine-candidate-induces-neutralizing-antibodies-in-nonhuman-primates 2026-02-04T01:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/sanegenebio-secures-1-5-billion-rnai-licensing-deal-with-genentech 2026-02-04T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/dash-bio-opens-24000-square-foot-glp-compliant-facility-to-accelerate-drug-development-bioanalysis 2026-02-04T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-secures-japanese-patent-for-autism-spectrum-disorder-therapeutic-mb-204 2026-02-04T01:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/quest-diagnostics-launches-noninvasive-blood-test-for-multiple-myeloma-residual-disease-monitoring 2026-02-04T01:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-discontinues-cystic-fibrosis-gene-therapy-while-advancing-eur25-billion-r-d-investment-plan 2026-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-seattle-facility-receives-brazilian-gmp-certification-opening-access-to-40-billion-south-american-market 2026-02-03T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-partners-with-samsung-biologics-to-strengthen-global-vaccine-manufacturing-for-future-pandemics 2026-02-03T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-early-alert-for-impella-heart-pump-sensor-malfunction-linked-to-22-patient-injuries 2026-02-03T21:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/zipbio-and-meiragtx-partner-to-develop-ai-designed-gene-therapy-for-geographic-atrophy 2026-02-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/mapi-pharma-reports-promising-phase-ii-results-for-ga-depot-in-primary-progressive-multiple-sclerosis 2026-02-03T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/neomorph-doses-first-patient-in-phase-1-2-trial-of-neo-811-molecular-glue-degrader-for-advanced-renal-cell-carcinoma 2026-02-03T21:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/gentherm-submits-fda-510-k-application-for-first-of-kind-patient-warming-and-securement-system 2026-02-03T17:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/tsc-life-receives-fda-clearance-for-pediatric-use-of-fluido-r-compact-blood-and-fluid-warming-system 2026-02-03T17:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/allarity-therapeutics-opens-phase-2-trial-combining-stenoparib-with-temozolomide-for-relapsed-small-cell-lung-cancer 2026-02-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-appoints-thomas-civik-as-interim-ceo-to-advance-micvo-cancer-therapy-development 2026-02-03T17:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-slowing-age-related-macular-degeneration-progression 2026-02-03T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/merck-forecasts-2026-revenue-below-wall-street-estimates-as-patent-cliff-looms 2026-02-03T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/hookipa-pharma-sells-oncology-assets-including-hpv-and-kras-targeted-therapies-to-neotrail-therapeutics 2026-02-03T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-approves-promega-s-msi-detection-kit-as-companion-diagnostic-for-keytruda 2026-02-03T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-licenses-novel-rsv-monoclonal-antibody-from-gates-medical-research-institute 2026-02-03T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/valo-health-names-novo-nordisk-veteran-karin-conde-knape-as-chief-scientific-officer 2026-02-03T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-s-valiltramiprosate-shows-promising-biomarker-results-in-phase-3-alzheimer-s-trial 2026-02-03T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-submits-upadacitinib-for-vitiligo-treatment-potentially-first-systemic-therapy-for-autoimmune-skin-disease 2026-02-03T17:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-discontinues-claudin-6-adc-ds-9606-following-strategic-portfolio-review 2026-02-03T17:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/baysient-expands-precision-dosing-platform-to-17-inflammatory-disease-indications-with-idose-gen7-0-launch 2026-02-03T17:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/preciseonco-consortium-secures-eur14-9-million-eu-grant-to-advance-ai-powered-precision-cancer-treatment 2026-02-03T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/biosion-initiates-phase-1-trial-of-bsi-082-anti-sirpa-antibody-for-advanced-solid-tumors 2026-02-03T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/expres2ion-biotech-reports-promising-immune-response-data-from-her2-targeting-cancer-vaccine-phase-i-trial 2026-02-03T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/hemostod-secures-chf-2-million-innosuisse-grant-to-advance-universal-donor-free-platelet-technology 2026-02-03T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-metastasis-directed-therapy-benefits-for-oligometastatic-prostate-cancer 2026-02-03T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-plans-1500-member-scientific-cadre-to-accelerate-drug-approvals-and-meet-global-standards 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-astrazeneca-s-subcutaneous-lupus-drug-saphnelo-despite-eu-approval 2026-02-03T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/pharming-advances-rare-disease-pipeline-with-napazimone-for-mitochondrial-disease-and-leniolisib-expansion 2026-02-03T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/large-swedish-study-finds-no-link-between-covid-19-vaccines-and-reduced-fertility 2026-02-03T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/persica-pharmaceuticals-pp353-shows-promising-results-for-chronic-low-back-pain-in-phase-1b-trial-published-in-the-lancet 2026-02-03T09:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/nmd-pharma-s-ignaseclant-shows-promise-in-phase-2a-trial-for-charcot-marie-tooth-disease 2026-02-03T09:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/vtv-therapeutics-expands-global-partnership-with-newsoara-for-pde4-inhibitor-hpp737-in-135-million-deal 2026-02-03T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-reduce-gout-medication-burden-in-patients-with-type-2-diabetes 2026-02-03T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/salspera-files-ipo-to-fund-phase-3-trial-of-saltikva-bacterial-immunotherapy-for-pancreatic-cancer 2026-02-03T01:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-files-ind-application-for-magsense-targeted-imaging-agent-in-her2-positive-breast-cancer 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-supported-mammography-screening-demonstrates-superior-cancer-detection-in-large-swedish-trial 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-completes-enrollment-in-phase-2-lotus-trial-for-hidradenitis-suppurativa-treatment 2026-02-03T01:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-proposes-ministerial-reliance-order-to-accelerate-drug-approvals-through-foreign-regulatory-collaboration 2026-02-03T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-secures-nmpa-approval-for-advanced-ophthalmic-microscopes-in-china 2026-02-03T01:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/novel-stroke-rehabilitation-approach-targeting-good-arm-shows-significant-motor-improvements-in-phase-ii-trial 2026-02-03T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-approves-reimbursement-for-fruzaqla-in-metastatic-colorectal-cancer-treatment 2026-02-02T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/australia-launches-world-first-personalized-mrna-vaccine-trial-for-pediatric-brain-cancer 2026-02-02T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-launches-tablet-in-capsule-technology-for-enhanced-drug-delivery 2026-02-02T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-names-susan-keefe-as-cfo-to-advance-somatic-genomics-platform 2026-02-02T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/sanegenebio-secures-1-7-billion-rnai-licensing-deal-with-genentech 2026-02-02T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/ensem-therapeutics-expands-etx-636-trial-to-china-targeting-pi3ka-mutations-in-cancer 2026-02-02T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-secures-u-s-patent-for-cannabinoid-enhanced-antimicrobial-platform-targeting-mrsa-and-antibiotic-resistance 2026-02-02T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-therapeutics-launches-investigator-initiated-study-for-once-daily-cystinosis-treatment 2026-02-02T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/teva-canada-partners-with-novartis-to-commercialize-multiple-sclerosis-treatment-mayzent 2026-02-02T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-canada-launches-first-ophthalmology-biosimilar-enzeevu-for-retinal-diseases 2026-02-02T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/acurx-pharmaceuticals-secures-new-patent-for-dna-polymerase-iiic-inhibitors-targeting-antibiotic-resistant-bacteria 2026-02-02T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/oxybutynin-demonstrates-significant-efficacy-in-reducing-hot-flashes-for-prostate-cancer-patients-on-hormone-therapy 2026-02-02T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/crystalys-therapeutics-expands-phase-3-ruby-study-to-europe-for-gout-treatment-dotinurad 2026-02-02T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/erleada-shows-51-reduction-in-death-risk-versus-darolutamide-in-real-world-prostate-cancer-study 2026-02-02T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/en-carta-diagnostics-receives-fda-breakthrough-device-designation-for-revolutionary-lyme-disease-test 2026-02-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-partners-with-university-of-minnesota-to-advance-carbohydrate-based-therapeutics-through-nmr-research 2026-02-02T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/jumo-health-launches-prism-system-to-address-clinical-trial-patient-readiness-and-retention-challenges 2026-02-02T17:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-advances-toward-phase-2a-trial-for-first-in-class-concussion-treatment-onp-002 2026-02-02T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-returns-rna-editing-drug-wve-006-to-wave-life-sciences-following-disappointing-aatd-trial-data 2026-02-02T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/biorce-raises-52-5-million-series-a-to-transform-clinical-trials-with-ai-platform 2026-02-02T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/southern-research-partners-with-pathogenus-to-expand-global-reach-in-respiratory-disease-and-cancer-research 2026-02-02T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-partners-with-sandoz-to-expand-biosimilar-access-across-canada-australia-and-new-zealand 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/gameto-licenses-harvard-meiosis-technology-to-advance-human-ovary-in-a-dish-platform-for-women-s-health 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/kahimmune-therapeutics-secures-exclusive-license-for-dark-genome-cancer-vaccine-platform 2026-02-02T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-supreme-court-to-determine-competition-commission-s-authority-over-patent-related-antitrust-cases 2026-02-02T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-vision-acquires-mdco-technology-s-ophthalmic-device-business-to-create-integrated-drug-device-platform 2026-02-02T05:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/nice-withdraws-car-t-therapy-tecartus-from-nhs-despite-patient-advocacy-appeals 2026-02-02T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/international-consortium-develops-revolutionary-platform-to-predict-human-antibody-drug-responses 2026-02-02T05:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/texas-cardiac-arrhythmia-institute-performs-first-u-s-implantation-of-fda-approved-miniaturized-defibrillation-lead 2026-02-02T05:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-insti-hiv-treatment-shows-promise-in-phase-3-trial-amid-rising-resistance-concerns 2026-02-02T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/reata-pharmaceuticals-shifts-focus-to-omaveloxolone-commercialization-following-friedreich-s-ataxia-approval 2026-02-02T01:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/scot-trial-confirms-3-month-adjuvant-chemotherapy-noninferior-to-6-month-standard-for-colorectal-cancer 2026-02-02T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-hansoh-pharma-advance-next-generation-her2-targeted-adc-gsk5764227-in-early-clinical-trials 2026-02-01T21:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/india-announces-rs-10000-crore-biopharma-shakti-initiative-and-cdsco-regulatory-overhaul-in-union-budget-2026 2026-02-01T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-rs-10000-crore-biopharma-shakti-initiative-and-exempts-17-cancer-drugs-from-import-duties 2026-02-01T09:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/tenacia-biopharmaceuticals-partners-with-golden-age-health-to-launch-first-cdkl5-deficiency-disorder-treatment-in-china 2026-02-01T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-bans-stem-cell-therapy-for-autism-outside-clinical-trials-declares-practice-medical-malpractice 2026-02-01T09:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/olema-pharmaceuticals-faces-leadership-transition-as-pivotal-breast-cancer-trial-data-approaches 2026-02-01T09:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/trace-biosciences-receives-fda-ind-clearance-for-first-in-class-nerve-specific-imaging-agent-lgw16-03 2026-02-01T09:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/cbd-shows-promise-in-reducing-fetal-alcohol-spectrum-disorder-effects-through-endocannabinoid-system-modulation 2026-02-01T00:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-completes-long-term-real-world-study-of-nucala-in-rare-eosinophilic-disease-egpa 2026-02-01T00:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/ardena-completes-divestment-of-swedish-api-manufacturing-site-to-nanologica 2026-01-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-lawmakers-propose-patent-break-for-eli-lilly-s-mounjaro-as-ozempic-patent-expires 2026-01-31T13:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/nasal-spray-h5n1-vaccine-shows-near-complete-protection-in-early-animal-studies 2026-01-31T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-secures-fda-approval-for-generic-lacosamide-oral-solution-for-epilepsy-treatment 2026-01-31T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/vivosim-labs-expands-human-based-toxicology-services-to-asia-pacific-through-strategic-distribution-partnerships 2026-01-31T01:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-patent-litigation-wave-intensifies-in-q4-2025-as-generic-manufacturers-challenge-key-drug-patents 2026-01-31T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-builds-1-5-billion-pre-launch-inventory-for-oral-glp-1-obesity-drug-ahead-of-fda-decision 2026-01-30T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-completes-350-million-acquisition-of-somalogic-to-expand-proteomics-leadership 2026-01-30T21:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/kyowa-kirin-regains-control-of-rocatinlimab-development-following-amgen-partnership-termination 2026-01-30T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-cmo-jacqueline-miller-steps-down-as-company-seeks-to-expand-beyond-covid-vaccines 2026-01-30T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-positive-phase-iii-results-for-fabhalta-in-rare-kidney-disease-c3-glomerulopathy 2026-01-30T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-partners-with-origami-therapeutics-on-protein-degrader-program-for-rare-neurodegenerative-diseases 2026-01-30T21:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/kos-biotechnology-partners-makes-inaugural-investment-in-epikast-s-technology-enabled-pharma-services-platform 2026-01-30T21:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-restructures-r-d-leadership-as-executive-vp-berman-departs 2026-01-30T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-unveils-first-in-class-nuclear-pd-l1-degrader-ndl2-targeting-immunotherapy-resistance 2026-01-30T17:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-16-million-pipe-investment-to-advance-cns-cancer-therapies 2026-01-30T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-of-needle-free-nasal-epinephrine-spray-for-pediatric-anaphylaxis 2026-01-30T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-data-integrity-review-of-amgen-s-tavneos-following-concerns-over-pivotal-advocate-study 2026-01-30T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-emerges-as-first-proven-intervention-to-prevent-long-covid-in-adults 2026-01-30T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/brain-swelling-from-alzheimer-s-drugs-may-signal-treatment-success-new-research-suggests 2026-01-30T13:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/poxel-emerges-from-judicial-reorganization-with-court-approved-recovery-plan 2026-01-30T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-frostbite-drug-iloprost-shows-zero-amputation-rate-in-clinical-use-at-ohio-hospitals 2026-01-30T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/sciwind-biosciences-receives-chinese-approval-for-glp-1-diabetes-drug-xianyida 2026-01-30T09:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-advances-hmbd-002-to-phase-ii-following-positive-safety-data-in-cancer-trial 2026-01-30T05:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-bioelectronic-patch-enables-precision-drug-delivery-to-complex-organs 2026-01-30T05:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-hiring-rebounds-as-companies-embrace-remote-work-and-ai-skills 2026-01-30T03:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-pharmaceuticals-raises-94-6-million-to-advance-drug-pipeline-in-neuropathic-pain-and-hypertrophic-cardiomyopathy 2026-01-30T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/metp-pharma-s-nose-to-brain-technology-achieves-superior-peptide-delivery-compared-to-blood-brain-barrier-shuttles 2026-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-m-a-surge-expected-as-200-billion-patent-cliff-drives-big-pharma-acquisition-strategy 2026-01-30T01:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-combination-therapy-shows-remarkable-success-in-metastatic-esophageal-cancer-patient 2026-01-30T01:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bite-immunotherapy-reduces-arterial-plaque-in-preclinical-atherosclerosis-study 2026-01-29T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-bead-free-microfluidics-method-to-streamline-car-t-cell-manufacturing 2026-01-29T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/geneva-team-wins-pfizer-prize-for-personalized-cancer-vaccine-mvx-onco-1-showing-clinical-benefit-in-advanced-tumors 2026-01-29T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-repertoire-immune-medicines-in-1-93-billion-autoimmune-disease-deal 2026-01-29T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/nucleic-acid-therapeutics-contract-manufacturing-market-surges-to-33-84-billion-by-2033 2026-01-29T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/breakthru-medicine-emerges-from-stealth-with-60m-series-a-to-develop-novel-cancer-therapeutics 2026-01-29T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/pulmonary-arterial-hypertension-pipeline-expands-with-55-therapies-as-merck-s-winrevair-shows-76-mortality-risk-reduction 2026-01-29T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/micurx-receives-fda-clearance-to-advance-mrx-5-into-phase-2a-trial-for-mycobacterium-abscessus-pulmonary-disease 2026-01-29T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-receives-milestone-payment-from-takeda-as-atac-based-adc-enters-phase-i-ii-trial 2026-01-29T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-advances-multi-platform-pipeline-with-prolectin-m-under-fda-ind-and-oxygen-transport-programs 2026-01-29T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-s-ai-designed-gipr-antagonist-ism0676-achieves-31-3-weight-loss-in-preclinical-studies 2026-01-29T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-jcog0603-trial-results-show-no-overall-survival-benefit-from-adjuvant-mfolfox6-after-liver-resection-for-colorectal-metastases 2026-01-29T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/dod-awards-genomind-contract-to-implement-pharmacogenomics-testing-for-active-duty-service-members 2026-01-29T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/panakeia-s-ai-software-achieves-landmark-validation-for-rapid-colorectal-cancer-molecular-profiling 2026-01-29T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-meta-analysis-finds-no-significant-vision-risk-from-glp-1-receptor-agonists-in-80000-patients 2026-01-29T17:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-reports-second-partial-response-for-wee1-inhibitor-apr-1051-in-phase-1-endometrial-cancer-trial 2026-01-29T13:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-pritelivir-demonstrates-superior-efficacy-in-phase-3-trial-for-drug-resistant-hsv-infections 2026-01-29T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/pre-surgical-pembrolizumab-achieves-71-complete-response-rate-in-desmoplastic-melanoma-trial 2026-01-29T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/darolutamide-receives-third-approval-in-china-for-metastatic-hormone-sensitive-prostate-cancer 2026-01-29T13:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-seysara-for-moderate-to-severe-acne-treatment-in-patients-9-years-and-older 2026-01-29T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-initiates-phase-ii-trial-of-inna-051-nasal-spray-for-viral-respiratory-infection-prevention 2026-01-29T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/oncoinvent-expands-phase-2-trial-sites-for-radspherin-radiopharmaceutical-in-ovarian-cancer 2026-01-29T13:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-qualifies-moleculightdx-as-medical-device-development-tool-for-wound-care-innovation 2026-01-29T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-strengthens-board-with-beigene-s-former-cmo-as-oncomimics-platform-shows-promise-in-cancer-trials 2026-01-29T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/eyestem-receives-cdsco-approval-for-phase-2-trial-of-stem-cell-therapy-for-dry-amd 2026-01-29T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-receives-fda-ind-clearance-for-ser-252-parkinson-s-disease-therapy 2026-01-29T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/qurebio-s-q-1802-bispecific-antibody-shows-70-response-rate-in-advanced-gastric-cancer-phase-ii-trial 2026-01-29T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/avobis-bio-reports-positive-expanded-stomp2-trial-results-for-crohn-s-perianal-fistula-cell-therapy 2026-01-29T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-receives-michael-j-fox-foundation-grant-to-develop-trpml1-biomarkers-for-parkinson-s-disease 2026-01-29T05:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabtech-and-sai-life-sciences-form-strategic-partnership-to-expand-eyra-immunology-platform-access-in-us-market 2026-01-29T05:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-launches-first-in-class-universal-coronavirus-vaccine-trial-targeting-entire-sarbecovirus-family 2026-01-29T05:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-biopharmaceuticals-advances-osteoarthritis-program-with-peer-reviewed-validation-of-injectable-pps 2026-01-29T05:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia-treatment 2026-01-29T05:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-files-first-orencia-biosimilar-application-with-fda-targeting-2-77-billion-market 2026-01-29T01:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/eric-schmidt-backed-ai-biotech-hologen-seeks-150-million-to-de-risk-clinical-trials 2026-01-28T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/calcimedica-halts-phase-ii-kidney-injury-trial-following-safety-concerns-stock-plummets-75 2026-01-28T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/enzian-pharmaceutics-expandable-fibrous-dosage-form-triples-bioavailability-of-sparingly-soluble-drugs 2026-01-28T21:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-biosciences-strengthens-board-with-former-bristol-myers-squibb-cmo-samit-hirawat 2026-01-28T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/unravel-biosciences-partners-with-scn2a-foundation-to-target-loss-of-function-mutations-in-autism-and-epilepsy 2026-01-28T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/siren-biotechnology-receives-fda-clearance-for-first-aav-based-cancer-gene-therapy-ind 2026-01-28T21:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/solriamfetol-shows-promise-for-treating-excessive-sleepiness-in-early-morning-shift-workers 2026-01-28T21:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/halo-pharma-emerges-as-independent-cdmo-following-noramco-group-divestiture-to-siegfried 2026-01-28T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-accepts-cipher-pharmaceuticals-new-drug-submission-for-natroba-spinosad-to-treat-head-lice-and-scabies 2026-01-28T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/ardelyx-initiates-phase-3-accel-trial-for-ibsrela-in-chronic-idiopathic-constipation 2026-01-28T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/sensorion-secures-eur60m-funding-round-led-by-sanofi-to-advance-gene-therapy-pipeline-for-hearing-loss 2026-01-28T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/eliquis-faces-major-patent-cliff-as-european-exclusivity-expires-in-may-2026 2026-01-28T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-receives-fda-clearance-for-first-ever-cellular-rejuvenation-therapy-using-epigenetic-reprogramming 2026-01-28T17:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-seamless-therapeutics-in-1-1-billion-gene-editing-deal-for-hearing-loss 2026-01-28T17:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/nine-marker-molecular-signature-identified-as-driver-of-lapatinib-resistance-in-her2-positive-breast-cancer 2026-01-28T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/onkure-faces-critical-data-readout-for-h1047r-specific-pi3ka-inhibitor-as-competition-intensifies 2026-01-28T17:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-brain-targeting-exosome-platform-delivers-curcumin-across-blood-brain-barrier-for-parkinson-s-disease 2026-01-28T17:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-larger-vial-size-of-nelarabine-injection-for-t-cell-leukemia-and-lymphoma-treatment 2026-01-28T17:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplant-capsules-show-breakthrough-results-in-cancer-immunotherapy-trials 2026-01-28T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-to-present-tpip-data-at-pvri-2026-congress-including-phase-3-palm-pah-study-design 2026-01-28T17:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-advances-castanospermine-development-with-florida-state-university-license 2026-01-28T17:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-repeat-administration-of-idose-tr-intracameral-implant-for-glaucoma-treatment 2026-01-28T17:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-based-medicines-show-mixed-results-for-fibromyalgia-pain-management 2026-01-28T13:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-pharmaceuticals-prepares-for-q4-results-with-amvuttra-sales-surge-and-pipeline-advances 2026-01-28T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-transplantation-shows-promise-in-enhancing-cancer-immunotherapy-across-multiple-tumor-types 2026-01-28T13:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/life-biosciences-secures-first-fda-approval-for-human-epigenetic-reprogramming-trial-to-reverse-vision-loss 2026-01-28T13:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/altido-therapeutics-raises-12-5m-to-advance-car-t-therapy-for-glioblastoma 2026-01-28T13:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-biomarker-blood-panel-shows-promise-for-early-pancreatic-cancer-detection 2026-01-28T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-launches-automated-ptau-217-csf-assay-for-alzheimer-s-disease-research 2026-01-28T09:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-s-apecotrep-shows-40-proteinuria-reduction-in-phase-ii-trial-for-rare-kidney-disease-fsgs 2026-01-28T09:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-topical-crispr-gene-therapy-successfully-corrects-disease-causing-mutations-in-human-skin 2026-01-28T05:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/leading-cancer-researchers-unite-to-accelerate-therapeutic-cancer-vaccine-development 2026-01-28T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/icotrokinra-demonstrates-superior-efficacy-over-oral-therapies-in-psoriasis-meta-analysis 2026-01-28T05:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/cranius-therapeutics-secures-20m-series-b-to-advance-blood-brain-barrier-bypass-platform 2026-01-28T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/genyro-secures-exclusive-license-for-sidewinder-dna-construction-technology-with-one-in-million-error-rate 2026-01-28T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-clarifies-patent-eligibility-standards-for-machine-learning-technologies-in-healthcare-innovation 2026-01-28T01:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/swiftstart-announces-80-million-strategic-investment-intent-in-tirx-at-1-50-per-share 2026-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kalaris-therapeutics-to-present-first-in-human-data-for-novel-dual-targeting-amd-therapy-th103 2026-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/outset-medical-s-next-generation-tablo-hemodialysis-system-receives-fda-clearance-with-enhanced-cybersecurity 2026-01-27T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/myra-vision-initiates-first-in-us-trial-of-adjustable-glaucoma-shunt-system 2026-01-27T21:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/starkage-therapeutics-partners-with-gustave-roussy-to-advance-first-in-class-senolytic-adc-for-digestive-cancers 2026-01-27T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/northwell-health-opens-psychedelics-research-center-to-advance-mental-health-treatments 2026-01-27T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/drug-farm-s-df-003-receives-fda-fast-track-designation-for-rosah-syndrome-treatment 2026-01-27T21:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/uva-scientists-develop-revolutionary-vaccine-platform-promising-3-week-development-timeline 2026-01-27T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/hyaluronidase-co-administration-enhances-cancer-immunotherapy-efficacy-through-subcutaneous-delivery 2026-01-27T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/ixcells-biotechnologies-and-rosebud-biosciences-form-strategic-partnership-to-advance-3d-organoid-models-for-rare-disease-drug-development 2026-01-27T17:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-seeks-orphan-drug-status-for-vt-1953-as-independent-analysis-values-asset-at-1-billion-post-phase-3 2026-01-27T17:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/trexbio-secures-50m-to-advance-novel-regulatory-t-cell-therapy-for-atopic-dermatitis 2026-01-27T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/abli-therapeutics-partners-with-michael-j-fox-foundation-to-test-risvodetinib-in-parkinson-s-prevention-trial 2026-01-27T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-s-ips-test-outperforms-standard-biomarkers-in-predicting-immunotherapy-response 2026-01-27T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-launches-first-mertk-gene-therapy-clinical-trial-for-rare-inherited-blindness 2026-01-27T17:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-intellia-s-crispr-gene-therapy-for-rare-nerve-disease 2026-01-27T17:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/bial-s-phase-2b-activate-study-reaches-75-completion-milestone-for-gba1-associated-parkinson-s-disease-treatment 2026-01-27T17:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-prevent-age-related-kidney-deterioration-in-breakthrough-aging-model-study 2026-01-27T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelberg-acquires-novel-dual-target-ibd-therapy-in-eur1-05-billion-deal-with-simcere 2026-01-27T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/skyhawk-therapeutics-reports-promising-nine-month-data-for-huntington-s-disease-drug-sky-0515 2026-01-27T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-secures-1-5-million-financing-and-appoints-new-ceo-to-advance-cancer-drug-pipeline 2026-01-27T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-demonstrates-sleep-driven-clearance-of-alzheimer-s-proteins-in-human-brain 2026-01-27T13:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-new-cell-and-gene-therapy-regulations-set-to-accelerate-clinical-development-starting-may-1 2026-01-27T13:57:05+00:00 hourly 0.9 https://trial.medpath.com/news/icr-develops-first-standardized-guidelines-for-patient-reported-outcomes-in-early-cancer-drug-trials 2026-01-27T13:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/prospera-test-reduces-need-for-invasive-lung-transplant-biopsies-by-75-in-ohio-state-study 2026-01-27T13:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/skyx-technologies-secures-25-million-funding-and-expands-smart-home-platform-with-nvidia-collaboration 2026-01-27T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-experimental-obesity-drug-ct-388-achieves-22-5-weight-loss-in-phase-ii-trial 2026-01-27T09:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/qilu-pharmaceutical-partners-with-insilico-medicine-in-120-million-ai-driven-metabolic-disease-drug-development-deal 2026-01-27T09:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-review-of-ohtuvayre-for-copd-maintenance-treatment 2026-01-27T09:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/avant-technologies-advances-cell-in-a-box-technology-for-immunosuppression-free-diabetes-therapy-at-epita-symposium 2026-01-27T03:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/ret-fusion-targeted-therapies-market-projected-for-significant-growth-through-2034 2026-01-27T03:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/gri-bio-secures-patent-protection-for-novel-nkt-cell-targeting-compounds-across-inflammatory-diseases 2026-01-27T03:43:58+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-receives-fda-clearance-for-phase-3-trial-of-iscib1-immunobody-in-advanced-melanoma 2026-01-27T03:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/alphamab-advances-first-pd-l1-x-vegfr2-antibody-drug-conjugate-jskn027-into-clinical-trials 2026-01-27T03:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/keros-therapeutics-advances-ker-065-for-duchenne-muscular-dystrophy-following-fda-orphan-drug-designation 2026-01-27T03:39:17+00:00 hourly 0.9 https://trial.medpath.com/news/fortitude-biomedicines-launches-with-13m-seed-funding-to-advance-novel-glue-dac-platform-for-cancer-and-autoimmune-diseases 2026-01-27T03:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-provides-development-pathway-for-novel-women-s-testosterone-therapy-with-reduced-breast-cancer-risk 2026-01-27T03:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-launches-phase-2-trial-testing-heart-protection-strategies-for-prostate-cancer-patients-on-hormone-therapy 2026-01-27T03:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-advances-to-clinical-obesity-trials-despite-inconclusive-preclinical-results 2026-01-27T03:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-at-home-4-in-1-respiratory-test-for-infants-and-adults 2026-01-27T03:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/primmune-therapeutics-raises-8-6m-to-advance-tlr7-agonist-prtx007-into-phase-2-melanoma-trial 2026-01-27T03:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-targeting-connexin-43-shows-promise-for-treating-inherited-heart-disease-in-young-athletes 2026-01-27T03:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/focus-graphite-secures-canadian-patent-for-silicon-enhanced-graphite-anode-technology 2026-01-27T03:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/novaliq-receives-fda-ind-clearance-for-nov05-phase-ii-trial-in-non-infectious-anterior-uveitis 2026-01-27T03:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/cabozantinib-temozolomide-combination-shows-promise-in-advanced-leiomyosarcoma-with-74-disease-control-rate 2026-01-27T03:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-launches-phase-2-trial-of-lb-102-for-bipolar-depression-following-positive-schizophrenia-results 2026-01-27T03:30:45+00:00 hourly 0.9 https://trial.medpath.com/news/mair-therapeutics-partners-with-radboud-university-to-advance-novel-tmem175-agonists-for-parkinson-s-disease 2026-01-27T03:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/leios-therapeutics-partners-with-bnc-korea-for-10xb-101-fat-reduction-treatment-development 2026-01-27T03:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-expanded-access-program-for-stemcyte-s-cord-blood-therapy-following-successful-long-covid-trial 2026-01-27T03:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-s-xifaxan-successor-fails-phase-iii-trials-for-hepatic-encephalopathy-prevention 2026-01-27T03:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-reports-positive-phase-1-results-for-world-s-first-bioengineered-liver-device-in-acute-liver-failure 2026-01-27T03:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-launches-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-in-u-s 2026-01-27T03:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/merz-therapeutics-seeks-european-approval-for-xeomin-in-pediatric-spasticity-treatment 2026-01-27T03:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/cxcr4-engineering-transforms-car-t-cell-therapy-enhanced-memory-formation-and-durable-anti-leukemic-immunity 2026-01-27T03:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-gene-therapy-during-heart-bypass-surgery-targets-vessel-longevity-in-scotland 2026-01-27T03:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-stark-survival-differences-in-multiple-myeloma-treatment-across-england 2026-01-27T03:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/moyom-biotechnology-partners-with-wpp-group-to-advance-aphranel-s-global-brand-strategy-in-regenerative-aesthetics 2026-01-27T03:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/oric-pharmaceuticals-gains-36-following-positive-cancer-data-and-strategic-partnerships 2026-01-27T03:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-s-sirna-therapeutic-bw-20829-enters-phase-2b-trial-for-elevated-lipoprotein-a-and-cardiovascular-disease 2026-01-27T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-first-quality-control-protocol-for-mesenchymal-stromal-cells-setting-new-therapeutic-standard 2026-01-27T03:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/lower-dose-venetoclax-shows-promise-for-chinese-patients-with-hematological-malignancies 2026-01-26T03:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-demonstrates-first-integrated-use-of-three-advanced-wound-care-technologies-at-boswick-symposium 2026-01-26T03:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/philippines-fda-advances-green-lane-initiative-to-fast-track-local-pharmaceutical-manufacturing-approvals 2026-01-26T03:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-oxldl-shows-promise-for-enhancing-pd-1-immunotherapy-in-osteosarcoma 2026-01-26T03:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/uk-life-sciences-companies-drive-ps3-7-billion-revenue-growth-in-sunday-times-tech-100 2026-01-26T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/avanos-medical-and-siemens-healthineers-form-strategic-partnership-to-advance-outpatient-pain-management-technologies 2026-01-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-medi-sciences-launches-nexipox-plus-varicella-vaccine-with-enhanced-stability-technology-for-indian-market 2026-01-25T13:47:14+00:00 hourly 0.9 https://trial.medpath.com/news/blinatumomab-linked-to-increased-epstein-barr-virus-reactivation-in-pre-transplant-patients 2026-01-25T13:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-receives-fda-clearance-for-automated-car-t-manufacturing-platform 2026-01-25T13:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-advances-two-adc-programs-with-q2-2026-data-readout-expected-for-cdh6-targeted-therapy 2026-01-25T13:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-faces-major-production-crisis-as-cancer-drug-manufacturing-halt-drives-57-profit-decline 2026-01-24T18:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-expands-rna-interference-portfolio-as-next-strategic-platform-following-radioligand-and-car-t-success 2026-01-24T18:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/axion-biosystems-acquires-cytotronics-high-density-cmos-mea-technology-to-advance-drug-discovery 2026-01-24T18:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-specialty-pharma-reports-26-revenue-decline-as-semaglutide-approval-delays-hit-q3-performance 2026-01-24T18:00:59+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-raises-115-million-in-upsized-public-offering-to-advance-metabolic-disease-pipeline 2026-01-24T04:39:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunis-reports-first-phase-2-data-for-secretome-based-biologic-showing-26-improvement-in-gait-speed-in-obese-seniors 2026-01-24T00:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/intuitive-surgical-receives-fda-clearance-for-da-vinci-5-robot-in-cardiac-procedures 2026-01-24T00:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/nih-s-recover-tlc-long-covid-trials-face-delays-won-t-begin-enrollment-until-summer-2026 2026-01-24T00:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/telyrx-digital-pharmacy-platform-goes-public-through-40-million-spac-transaction 2026-01-23T20:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/philip-morris-international-seeks-fda-authorization-for-zyn-as-modified-risk-tobacco-product 2026-01-23T20:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-s-red-c-phase-3-trial-fails-to-meet-primary-endpoint-in-hepatic-encephalopathy-prevention 2026-01-23T20:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/belimumab-demonstrates-sustained-long-term-benefits-for-cutaneous-lupus-in-real-world-study 2026-01-23T20:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-study-identifies-two-genes-as-predictive-biomarkers-for-cancer-immunotherapy-response 2026-01-23T20:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/privo-technologies-prv211-intraoperative-chemotherapy-patch-meets-primary-safety-endpoint-in-head-and-neck-cancer-trial 2026-01-23T20:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/blau-farmaceutica-achieves-historic-milestone-with-first-brazilian-developed-pembrolizumab-biosimilar 2026-01-23T20:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/naprod-life-sciences-secures-anvisa-gmp-certification-renewal-for-oncology-manufacturing-operations 2026-01-23T20:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-subcutaneous-biologics-set-to-transform-drug-delivery-as-industry-shifts-from-iv-administration 2026-01-23T20:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/atley-solutions-and-perceptive-discovery-form-strategic-partnership-to-advance-astatine-211-radiopharmaceutical-development 2026-01-23T20:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/cd137-targeted-therapies-advance-with-90-clinical-trials-spanning-multiple-cancer-types 2026-01-23T20:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/sinovac-secures-exclusive-hepatitis-a-vaccine-contract-in-oman-breaking-into-gcc-market 2026-01-23T20:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-outperform-traditional-diabetes-treatments-in-large-comparative-study 2026-01-23T16:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-secures-court-injunction-blocking-generic-diabetes-drug-launch-in-australia 2026-01-23T16:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-in-class-monoclonal-antibody-for-chronic-hepatitis-d-treatment 2026-01-23T16:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/doubling-dolutegravir-dosage-reduces-hiv-viral-reservoir-in-suppressed-patients 2026-01-23T16:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-t-cell-activator-itac-xs15-cll01-demonstrates-safety-and-immunogenicity-in-phase-1-chronic-lymphocytic-leukemia-trial 2026-01-23T16:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/choroideremia-research-foundation-acquires-spark-therapeutics-gene-therapy-assets-to-advance-rare-disease-treatment 2026-01-23T16:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/curative-biotechnology-secures-canadian-patent-for-novel-retinal-degeneration-target 2026-01-23T16:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/akums-secures-eu-gmp-certifications-for-two-haridwar-manufacturing-plants-expanding-european-market-access 2026-01-23T16:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-s-phase-3-red-c-trials-for-hepatic-encephalopathy-prevention-fail-to-meet-primary-endpoint 2026-01-23T16:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/musc-researchers-develop-novel-antibody-targeting-sfrp2-to-combat-triple-negative-breast-cancer-resistance 2026-01-23T12:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-targets-tumor-macrophages-to-overcome-immunotherapy-resistance-in-metastatic-cancer 2026-01-23T04:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-partners-with-university-of-colorado-to-accelerate-healthcare-innovation-in-ai-robotics-and-sustainability 2026-01-23T04:50:40+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-halts-new-vaccine-trial-investments-amid-us-policy-opposition 2026-01-23T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-rejects-abbvie-s-venetoclax-patent-application-opening-door-for-generic-competition 2026-01-23T00:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/concept-medical-initiates-global-stars-dapt-trial-for-polymer-free-drug-eluting-stent-in-stemi-patients 2026-01-23T00:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/mitocarex-bio-reports-positive-in-vitro-results-for-novel-mitochondrial-carrier-targeting-anti-inflammatory-compounds 2026-01-23T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-completes-700-million-acquisition-of-astria-therapeutics-to-strengthen-hereditary-angioedema-leadership 2026-01-23T00:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/florida-cancer-specialists-launches-phase-3-trial-of-pasritamig-bispecific-t-cell-engager-for-castration-resistant-prostate-cancer 2026-01-23T00:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/ellipses-in-licenses-first-in-class-b7h3-antibody-drug-conjugate-from-innolake-biopharm 2026-01-23T00:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulatory-agency-removes-two-prescriber-requirement-for-isotretinoin-in-under-18-patients 2026-01-23T00:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-combination-therapy-shows-promise-in-checkpoint-inhibitor-resistant-hodgkin-lymphoma 2026-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phasev-unveils-ai-powered-platform-to-accelerate-ibd-clinical-trials-through-predictive-site-selection 2026-01-22T20:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/spotitearly-partners-with-fox-chase-cancer-center-to-validate-ai-canine-breath-based-cancer-detection-technology 2026-01-22T20:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-partners-with-runway-health-to-expand-arakoda-access-for-malaria-prevention 2026-01-22T20:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/ace-inhibitors-show-significant-mortality-reduction-in-idiopathic-pulmonary-fibrosis-patients 2026-01-22T16:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/abatacept-shows-long-term-benefits-in-delaying-rheumatoid-arthritis-onset-by-up-to-four-years 2026-01-22T16:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-digital-health-deregulation-with-revised-guidance-on-wearables-and-clinical-decision-support-software 2026-01-22T16:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-approving-reduced-risk-marketing-claims-for-zyn-nicotine-pouches 2026-01-22T16:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-reports-100-response-rate-in-cancer-trial-reducing-disease-severity-by-half 2026-01-22T16:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/paq-therapeutics-initiates-first-in-human-trial-of-pan-kras-degrader-pt0511-secures-77-million-in-series-b-funding 2026-01-22T16:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-partners-with-janux-therapeutics-in-850m-tumor-activated-cancer-drug-deal 2026-01-22T16:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/biomerieux-acquires-accellix-for-eur35m-to-strengthen-cell-and-gene-therapy-quality-control-portfolio 2026-01-22T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/mendra-raises-82-million-series-a-to-transform-rare-disease-development-through-ai-driven-strategy 2026-01-22T16:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-technologies-partners-with-space-liintech-for-iss-based-protein-crystallization-research 2026-01-22T16:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/curant-rare-and-cencora-form-strategic-partnership-to-streamline-rare-disease-therapy-commercialization 2026-01-22T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/walmart-launches-clinical-research-sites-in-former-health-clinics-to-expand-trial-access-in-underserved-communities 2026-01-22T16:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/human-continuum-appoints-dr-omar-khalid-sial-as-chief-scientific-officer-to-advance-exosome-based-therapeutics-platform 2026-01-22T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-cuts-drug-trial-manufacturing-review-timeline-in-half-to-accelerate-pharmaceutical-development 2026-01-22T12:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/nerlynx-launches-in-thailand-as-new-her2-breast-cancer-treatment-option 2026-01-22T12:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/pulsesight-therapeutics-completes-phase-i-dosing-for-novel-gene-therapy-pst-611-in-geographic-atrophy 2026-01-22T12:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/caverstim-implantable-neurostimulator-shows-promise-in-first-in-man-study-for-post-prostatectomy-erectile-dysfunction 2026-01-22T12:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-to-present-phase-3-nizubaglustat-data-for-rare-lysosomal-storage-disorders-at-worldsymposium-2026 2026-01-22T12:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-pivots-to-biosimilars-and-glp-1-drugs-as-revlimid-revenue-cliff-approaches 2026-01-22T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-full-approval-for-potassium-bromide-chewable-tablets-to-treat-canine-idiopathic-epilepsy 2026-01-22T12:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/paltusotine-poised-for-major-market-impact-as-first-oral-acromegaly-therapy-gains-fda-approval 2026-01-22T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/strive-completes-225-million-follow-on-offering-rapidly-retires-92-of-semler-scientific-debt 2026-01-22T09:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/60-million-global-consortium-launches-to-accelerate-antibiotic-discovery-against-gram-negative-bacteria 2026-01-22T08:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-acquires-biotissue-s-surgical-and-wound-care-business-for-15-million 2026-01-22T08:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-partners-with-msd-and-hilleman-labs-on-30m-cepi-funded-zaire-ebola-vaccine-development 2026-01-22T08:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/puma-trial-challenges-standard-heart-surgery-monitoring-with-3-7m-study-comparing-invasive-devices 2026-01-22T08:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-initiates-pivotal-study-for-blood-pressure-control-after-spinal-cord-injury 2026-01-22T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmac-proposes-expanded-access-to-cystic-fibrosis-treatments-for-all-ages 2026-01-22T04:52:53+00:00 hourly 0.9 https://trial.medpath.com/news/anteris-technologies-raises-200-million-to-advance-aortic-stenosis-treatment-with-strategic-medtronic-partnership 2026-01-22T04:52:52+00:00 hourly 0.9 https://trial.medpath.com/news/sonomotion-receives-fda-clearance-for-break-wave-non-invasive-kidney-stone-treatment-device 2026-01-22T04:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/new-dark-borosilicate-contrast-agent-shows-promise-for-enhanced-ct-imaging-of-bowel-pathologies 2026-01-22T01:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-bnt113-mrna-immunotherapy-for-hpv16-positive-head-and-neck-cancer 2026-01-22T01:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-cepi-launch-30-million-initiative-to-develop-more-affordable-ebola-vaccine-for-low-income-countries 2026-01-22T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/news/alterity-therapeutics-advances-ath434-toward-phase-3-trial-in-multiple-system-atrophy-with-strengthened-clinical-data 2026-01-21T20:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/phasewell-research-partners-with-bio-behavioral-health-to-expand-neuropsychiatric-clinical-trial-access 2026-01-21T20:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-closes-22-5-million-financing-to-advance-gene-therapy-pipeline-for-blindness-diseases 2026-01-21T20:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/think-bioscience-raises-55m-series-a-to-develop-first-in-class-therapies-for-undruggable-targets 2026-01-21T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-9-1-q4-sales-growth-targets-100-5-billion-revenue-for-2026 2026-01-21T20:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/qv-bioelectronics-secures-ps4-5m-to-advance-world-first-implantable-brain-cancer-device-into-clinical-trials 2026-01-21T20:39:52+00:00 hourly 0.9 https://trial.medpath.com/news/infinitopes-secures-35m-to-advance-ai-powered-cancer-vaccine-for-esophageal-cancer-prevention 2026-01-21T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-secures-chinese-patent-for-ht-kit-cancer-program-targeting-kit-signaling-pathways 2026-01-21T20:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/obagi-medical-launches-aloha-program-for-real-world-evaluation-of-new-hyaluronic-acid-filler 2026-01-21T20:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/intrabio-s-levacetylleucine-achieves-primary-endpoint-in-pivotal-phase-iii-trial-for-ataxia-telangiectasia 2026-01-21T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-pegrizeprument-for-liver-transplant-rejection-prevention 2026-01-21T16:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-launches-ai-powered-paige-predict-for-biomarker-detection-in-digital-pathology 2026-01-21T16:14:12+00:00 hourly 0.9 https://trial.medpath.com/news/scynexis-receives-fda-fast-track-and-qidp-designations-for-scy-247-antifungal-therapy 2026-01-21T16:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-secures-fda-agreement-for-streamlined-gemini-approval-pathway-in-acute-kidney-injury 2026-01-21T16:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/sigachi-industries-develops-triple-drug-api-combination-for-cystic-fibrosis-treatment 2026-01-21T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-submits-ind-application-for-fg001-cancer-imaging-agent-to-begin-u-s-registration-trial 2026-01-21T13:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/ervimmune-raises-eur17-million-to-advance-off-the-shelf-cancer-vaccine-targeting-human-endogenous-retroviruses 2026-01-21T13:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-explores-strategic-alternatives-as-cancer-vaccine-developer-faces-financial-pressures 2026-01-21T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-triples-investment-to-2b-for-north-carolina-glp-1-manufacturing-plant-to-challenge-obesity-market-leaders 2026-01-21T07:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/variant-bio-appoints-craig-t-basson-as-chief-medical-officer-to-accelerate-genomics-driven-drug-discovery 2026-01-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-of-canada-to-rule-on-medical-treatment-patent-validity-in-landmark-janssen-case 2026-01-21T03:23:19+00:00 hourly 0.9 https://trial.medpath.com/news/engene-secures-125-million-debt-facility-to-advance-bladder-cancer-gene-therapy-toward-fda-approval 2026-01-21T03:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/biomodal-s-6-base-sequencing-technology-achieves-95-accuracy-in-early-stage-colorectal-cancer-detection 2026-01-21T03:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-advances-crispr-cholesterol-therapy-stx-1150-to-phase-i-trials-in-mid-2026 2026-01-21T03:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/isomorphic-labs-pushes-back-ai-designed-drug-clinical-trials-to-2026 2026-01-21T03:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-expands-holly-springs-manufacturing-investment-to-2-billion-for-obesity-drug-production 2026-01-21T03:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-secures-medicare-reimbursement-for-comprehensive-cancer-genomic-test-at-2989-per-test 2026-01-21T03:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/patent-disputes-highlight-innovation-challenges-in-photodynamic-therapy-and-genomic-sequencing-technologies 2026-01-21T03:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-guidelines-now-recognize-mammaprint-testing-to-guide-anthracycline-use-in-hr-her2-breast-cancer 2026-01-21T03:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/biomakers-secures-8-million-to-scale-ai-driven-precision-oncology-platform 2026-01-21T03:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/compremium-s-non-invasive-cvp-device-receives-fda-breakthrough-designation 2026-01-21T03:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/q1-2026-pharmaceutical-pipeline-poised-for-major-regulatory-milestones-across-multiple-therapeutic-areas 2026-01-20T16:45:11+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-and-aspect-biosystems-expand-partnership-to-develop-curative-cell-therapies-for-diabetes 2026-01-20T16:42:52+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-partners-with-microsoft-to-deploy-ai-powered-lung-cancer-detection-technology 2026-01-20T16:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/reunion-neuroscience-s-re104-meets-primary-endpoint-in-phase-2-postpartum-depression-trial-advances-to-phase-3 2026-01-20T16:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-partners-with-immunoact-to-bring-india-s-first-indigenous-car-t-cell-therapy-to-africa 2026-01-20T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/spur-therapeutics-to-present-two-year-clinical-data-for-flt201-gene-therapy-in-gaucher-disease-at-worldsymposium 2026-01-20T16:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/eur60-million-ligand-ai-consortium-launches-to-accelerate-drug-discovery-through-open-ai-datasets 2026-01-20T16:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/polarean-expands-xenon-mri-platform-into-cardiopulmonary-drug-development-with-multi-center-ph-ild-study 2026-01-20T16:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-receives-fda-orphan-drug-designation-for-bpm31510-in-primary-coq10-deficiency 2026-01-20T16:38:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-lilly-s-sofetabart-mipitecan-for-platinum-resistant-ovarian-cancer 2026-01-20T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-secures-cms-reimbursement-for-trusight-oncology-comprehensive-test-at-2989-55 2026-01-20T16:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/worldwide-clinical-trials-acquires-catalyst-clinical-research-to-strengthen-oncology-capabilities 2026-01-20T16:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/cjeu-to-rule-on-critical-spc-patent-protection-case-for-veterinary-drug-development 2026-01-20T16:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/cytespace-africa-labs-triples-molecular-testing-capacity-to-support-clinical-trials-across-sub-saharan-africa 2026-01-20T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/adaptin-bio-receives-first-irb-approval-for-novel-brain-cancer-immunotherapy-aptn-101-phase-1-trial 2026-01-20T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-increases-viiv-healthcare-stake-to-21-7-in-2-13-billion-deal-as-pfizer-exits-hiv-joint-venture 2026-01-20T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-completes-nyse-direct-listing-as-eu-recommends-imfinzi-for-gastric-cancer 2026-01-20T15:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-merck-cancer-vaccine-maintains-49-risk-reduction-in-high-risk-melanoma-at-five-year-mark 2026-01-20T15:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/hrv-pharma-and-haleos-labs-form-strategic-cdmo-alliance-to-accelerate-orphan-drug-api-development 2026-01-20T15:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-life-secures-first-fda-clearance-for-hypothermic-oxygenated-perfusion-system-in-liver-transplantation 2026-01-20T15:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-partners-with-vanderbilt-medical-center-in-five-year-drug-discovery-collaboration-for-cardiovascular-and-kidney-diseases 2026-01-20T14:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-rapt-therapeutics-for-2-2-billion-to-advance-food-allergy-treatment 2026-01-20T14:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/exciva-secures-eur51-million-series-b-to-advance-alzheimer-s-agitation-therapy-deraphan-into-phase-2-trials 2026-01-20T14:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/exciva-secures-eur51m-series-b-to-advance-alzheimer-s-agitation-treatment-into-phase-ii 2026-01-20T14:55:17+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-publishes-first-real-world-evidence-study-on-medical-cannabis-for-chronic-pain-management 2026-01-20T11:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/elekta-receives-fda-clearance-for-evo-ct-linac-system-expanding-u-s-radiation-oncology-capabilities 2026-01-20T00:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/functional-gut-clinic-launches-specialized-clinical-trials-division-to-accelerate-digestive-health-research 2026-01-20T00:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/nucleome-therapeutics-advances-first-in-class-inflammation-resolution-antibody-to-preclinical-development 2026-01-19T21:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/florida-cancer-affiliates-launches-clinical-trials-in-bay-county-bringing-advanced-cancer-treatments-closer-to-home 2026-01-19T21:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-airway-scaffolds-show-promise-in-breathe-3-trial-for-severe-emphysema-treatment 2026-01-19T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/iregene-s-nouvneu001-becomes-first-ipsc-therapy-to-receive-both-fda-fast-track-and-rmat-designations-for-parkinson-s-disease 2026-01-19T16:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-and-spyglass-raise-combined-350m-in-biotech-ipos-signaling-market-recovery 2026-01-19T16:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/debra-research-and-university-medical-center-groningen-launch-dedicated-clinical-trial-site-for-epidermolysis-bullosa 2026-01-19T14:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-extends-strategic-bristol-myers-squibb-collaboration-through-2035 2026-01-19T08:56:39+00:00 hourly 0.9 https://trial.medpath.com/news/lumos-diagnostics-advances-two-key-clinical-programs-with-1-1m-in-milestone-funding 2026-01-19T08:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-pursues-10-billion-acquisition-of-women-s-health-specialist-organon 2026-01-19T08:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/jw-pharmaceutical-secures-u-s-patent-for-novel-hair-loss-treatment-jw0061-targeting-gfra1-receptor 2026-01-19T08:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-proposes-streamlined-drug-approvals-through-foreign-regulatory-partnerships 2026-01-19T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-announces-strategic-acquisitions-and-leadership-changes-to-strengthen-drug-development-capabilities 2026-01-19T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-protein-degradation-technology-reveals-molecular-mechanisms-for-targeting-undruggable-diseases 2026-01-19T06:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-anti-cancer-resistance-drug-oct-598-begins-phase-1-clinical-trials-through-public-private-partnership 2026-01-18T16:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-lenvatinib-combination-shows-40-response-rate-in-recurrent-gynecologic-clear-cell-carcinoma 2026-01-17T20:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-secures-key-patent-for-alto-207-depression-treatment-extending-ip-protection-to-mid-2040s 2026-01-17T18:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-lancet-review-finds-no-link-between-paracetamol-use-during-pregnancy-and-autism-or-adhd-in-children 2026-01-17T18:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-therapeutics-raises-200-million-in-ipo-to-advance-fibrotic-disease-therapies 2026-01-17T15:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-extended-five-year-use-of-nexplanon-contraceptive-implant 2026-01-17T07:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-cancer-pipeline-with-mrna-4106-immunotherapy-trial-in-solid-tumors 2026-01-17T03:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-researchers-develop-freeze-dried-mrna-delivery-system-for-cancer-therapy 2026-01-17T03:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-for-sjogren-s-disease 2026-01-16T20:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-full-approval-to-laverdia-first-oral-treatment-for-canine-lymphoma 2026-01-16T20:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-expands-lumee-oxygen-monitoring-platform-through-strategic-partnerships-and-commercial-launch 2026-01-16T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-shows-gender-specific-efficacy-for-cannabis-use-disorder-in-phase-2-trial 2026-01-16T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-shows-superior-glaucoma-protection-compared-to-glp-1-receptor-agonists-in-type-2-diabetes-patients 2026-01-16T16:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-rejects-moderna-s-bid-to-shift-covid-19-vaccine-patent-liability-to-us-government 2026-01-16T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-s-cd19-car-nk-therapy-achieves-15-month-complete-response-in-waldenstrom-lymphoma 2026-01-16T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-raises-ps2-5m-to-advance-car-t-therapy-for-acute-myeloid-leukemia 2026-01-16T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/penpulimab-plus-anlotinib-shows-promise-in-resectable-nsclc-phase-ii-trial 2026-01-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-shows-promise-in-aggressive-meningiomas-with-specific-genetic-mutations 2026-01-16T16:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-landscape-shows-strong-activity-in-gout-and-bronchiectasis-research 2026-01-16T16:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-presents-preclinical-data-supporting-elunetirom-s-novel-neuroplasticity-mechanism-for-depression-treatment 2026-01-16T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-s-real-world-data-powers-fda-clearance-of-ai-powered-brain-hemorrhage-detection-software 2026-01-16T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/qps-holdings-implements-oracle-argus-platform-to-enhance-clinical-trial-safety-management 2026-01-16T13:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-drug-tlc-2716-reduces-triglycerides-by-38-and-remnant-cholesterol-by-61-in-phase-1-trial 2026-01-16T13:00:15+00:00 hourly 0.9 https://trial.medpath.com/news/large-uk-trial-finds-fda-cleared-adhd-device-ineffective-despite-safety-profile 2026-01-16T12:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/nous-209-neoantigen-vaccine-shows-promise-for-cancer-prevention-in-lynch-syndrome-carriers 2026-01-16T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/interim-analysis-shows-no-safety-concerns-for-rsv-vaccine-during-pregnancy 2026-01-16T12:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-nears-major-licensing-deal-for-subcutaneous-drug-delivery-platform-alt-b4 2026-01-16T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/brenig-therapeutics-initiates-first-in-human-trial-of-brain-selective-nlrp3-inhibitor-bt-409-for-neurodegenerative-diseases 2026-01-16T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/news/ingrezza-demonstrates-nearly-two-fold-higher-vmat2-target-occupancy-than-austedo-xr-in-head-to-head-study 2026-01-16T12:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-prices-850-million-senior-notes-to-fund-amicus-therapeutics-acquisition 2026-01-16T06:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/leads-biolabs-pd-l1-4-1bb-bispecific-antibody-receives-fda-fast-track-designation-for-rare-neuroendocrine-cancer 2026-01-16T04:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expanded-indications-for-cerapedics-pearlmatrix-bone-graft-across-all-major-lumbar-fusion-procedures 2026-01-16T04:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/frontage-cdmo-completes-gmp-validation-for-new-manufacturing-facility-supporting-clinical-and-commercial-production 2026-01-16T04:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-pegozafermin-leads-mash-treatment-rankings-for-fibrosis-regression-and-disease-resolution 2026-01-16T04:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-hiv-treatment-shows-high-acceptance-among-adolescents-in-global-clinical-trial 2026-01-16T04:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/orion-projects-nubeqa-sales-could-exceed-eur1-billion-annually-as-prostate-cancer-drug-drives-2026-growth 2026-01-15T22:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-prepares-enhanced-takeover-bid-for-ocular-therapeutix-following-rejected-16-per-share-offer 2026-01-15T22:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-febrile-seizure-warning-for-six-major-flu-vaccines-following-post-marketing-safety-analysis 2026-01-15T22:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-regn9533-blood-clot-treatment-through-phase-1-while-terminating-heart-failure-program 2026-01-15T22:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/qli5-therapeutics-secures-eur6-2m-to-advance-novel-proteasome-inhibitor-adc-platform 2026-01-15T22:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/remsleep-secures-expanded-fda-clearance-and-medicare-coding-for-deltawave-sleep-therapy-system 2026-01-15T22:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-generic-mifepristone-as-senate-committee-debates-drug-safety-protocols 2026-01-15T22:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-endure-trial-shows-no-benefit-of-ropeginterferon-alfa-2b-maintenance-after-tki-cessation-in-cml 2026-01-15T18:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-partners-with-wuxi-biologics-to-accelerate-next-generation-fusion-protein-development 2026-01-15T16:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-toward-china-market-entry-with-nmpa-submission 2026-01-15T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/lmu-researchers-develop-hybrid-nanocarrier-system-for-inhalable-mrna-vaccines 2026-01-15T16:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-presents-phase-3-data-on-relfydess-neuromodulator-at-toxins-2026-demonstrating-superior-efficacy-and-duration 2026-01-15T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-acquires-penumbra-for-14-5-billion-to-expand-vascular-pipeline 2026-01-15T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/ritlecitinib-shows-consistent-vitiligo-repigmentation-across-diverse-patient-subgroups-in-phase-2b-analysis 2026-01-15T16:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/propanc-biopharma-publishes-peer-reviewed-research-on-prp-s-impact-on-pancreatic-cancer-tumor-microenvironment 2026-01-15T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secure-trial-shows-promising-results-for-advanced-prostate-cancer-treatment 2026-01-15T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-fda-clearance-for-multi-modality-breast-biopsy-system-market-launch-planned-for-early-2026 2026-01-15T16:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-partners-with-immunai-to-deploy-ai-for-immune-response-analysis-in-clinical-trials 2026-01-15T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-patient-receives-alveltamig-novel-trispecific-t-cell-engager-for-small-cell-lung-cancer 2026-01-15T16:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/korea-university-researchers-revive-nk1-receptor-as-depression-target-through-novel-molecular-design 2026-01-15T16:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-report-positive-phase-ii-results-for-novel-sepsis-drug-stc3141 2026-01-15T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-secures-chinese-approval-for-two-breakthrough-therapies-targeting-rare-cardiovascular-and-metabolic-disorders 2026-01-15T16:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-leucovorin-for-autism-treatment-despite-limited-evidence 2026-01-15T16:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-pharmacy-sues-eli-lilly-and-novo-nordisk-over-alleged-glp-1-market-suppression 2026-01-15T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-arabia-becomes-first-country-to-approve-anktiva-for-lung-cancer-treatment 2026-01-15T09:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-upholds-ban-on-triple-drug-diabetes-combinations-supreme-court-to-review 2026-01-15T09:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-first-to-market-generic-olopatadine-0-7-eye-drops-in-us 2026-01-15T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-herpes-virus-based-therapy-shows-promise-in-glioblastoma-clinical-trial 2026-01-15T05:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/aim-vaccine-completes-phase-iii-trials-for-high-efficiency-diploid-rabies-vaccine-with-superior-efficacy 2026-01-15T05:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-pharmaceuticals-advances-proprietary-pipeline-with-novel-eye-drop-and-cancer-therapies 2026-01-15T05:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-advances-first-novel-adc-targeting-nectin-4-into-phase-1-trials-following-fda-clearance 2026-01-15T05:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/gradalis-vigil-immunotherapy-shows-nearly-six-year-survival-benefit-in-ovarian-cancer-subset 2026-01-15T00:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-flu-vaccine-reduces-hospitalizations-in-older-adults-with-diabetes-danish-trial-shows 2026-01-15T00:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/rina-s-shows-50-response-rate-in-heavily-pretreated-endometrial-cancer-regardless-of-target-expression 2026-01-15T00:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/adolore-biotherapeutics-receives-fda-orphan-drug-designation-for-gene-therapy-targeting-erythromelalgia 2026-01-15T00:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/alfasigma-acquires-exclusive-rights-to-adibelivir-for-hsv-encephalitis-in-eur125-million-deal 2026-01-15T00:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/iotamotion-receives-fda-clearance-for-pediatric-cochlear-implant-robot-expanding-access-for-children 2026-01-15T00:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-shows-lasting-benefits-for-severe-treatment-resistant-depression-in-two-year-study 2026-01-15T00:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/adial-pharmaceuticals-secures-patent-protection-for-ad04-alcohol-use-disorder-therapy-through-2045 2026-01-15T00:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/ultrahuman-and-click-therapeutics-launch-world-s-first-biomarker-driven-migraine-management-tool 2026-01-15T00:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-rayner-s-sophi-wireless-phacoemulsification-system-for-u-s-cataract-surgery-market 2026-01-15T00:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/caldera-therapeutics-launches-with-112-5m-to-advance-first-in-class-bispecific-ibd-therapy 2026-01-15T00:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/aragen-life-sciences-shifts-biologics-operations-to-india-as-global-pharma-rebalances-supply-chains 2026-01-14T20:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-identifies-small-cell-lung-cancer-patients-who-will-respond-to-tarlatamab-immunotherapy 2026-01-14T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-partners-with-tq-therapeutics-to-develop-point-of-care-cell-therapy-manufacturing-system 2026-01-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-secures-long-term-actinium-225-supply-deal-to-support-radioligand-therapy-expansion 2026-01-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-advances-weight-loss-drug-elecoglipron-to-phase-iii-as-company-targets-80b-revenue-by-2030 2026-01-14T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/nuclera-secures-87-million-series-c-extension-to-advance-ai-enabled-antibody-engineering-platform 2026-01-14T17:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-secures-european-approval-for-ondibta-insulin-glargine-biosimilar-targeting-66-million-european-diabetes-patients 2026-01-14T17:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-olumiant-for-adolescent-alopecia-areata-treatment 2026-01-14T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4-therapeutics-advances-cemsidomide-through-phase-2-development-as-potential-best-in-class-multiple-myeloma-treatment 2026-01-14T13:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-reports-record-4-3-billion-revenue-in-2025-prepares-zanidatamab-launch-for-gastroesophageal-cancer 2026-01-14T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/tbd09-tuberculosis-drug-candidate-completes-phase-i-trial-shows-promise-as-linezolid-alternative 2026-01-14T13:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-uk-patient-receives-nhs-funded-car-t-therapy-for-aggressive-leukemia-at-manchester-royal-infirmary 2026-01-14T13:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-breakthrough-device-program-maintains-steady-pace-as-medicare-coverage-debate-intensifies 2026-01-14T13:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/amplifi-vascular-receives-fda-breakthrough-device-designation-for-dialysis-access-innovation 2026-01-14T05:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/rituximab-shows-long-term-effectiveness-with-extended-dosing-intervals-in-relapsing-multiple-sclerosis 2026-01-14T05:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/roche-outlines-ambitious-pipeline-strategy-with-blockbuster-potential-assets-through-2031 2026-01-14T05:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-accelerates-ai-driven-drug-discovery-strategy-with-950m-35pharma-acquisition-and-noetik-partnership 2026-01-14T03:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-diverse-hiv-pipeline-offers-competitive-advantage-with-seven-candidates-in-development 2026-01-14T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/allele-biotechnology-partners-with-uc-san-diego-on-25-8m-arpa-h-project-to-develop-3d-bioprinted-livers-for-transplantation 2026-01-14T01:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/small-intracellular-vesicles-outperform-extracellular-vesicles-in-drug-delivery-and-retinal-protection 2026-01-14T00:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-projects-1-7-billion-revenue-by-2028-advances-alzheimer-s-psychosis-pipeline 2026-01-14T00:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/adimab-reports-11-new-clinical-programs-in-2025-reaching-89-total-programs-with-six-approved-therapies 2026-01-14T00:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-s-nasal-delivery-technology-advances-castlevax-phase-ii-covid-19-vaccine-trial 2026-01-14T00:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/axol-bioscience-secures-2-8m-to-expand-ipsc-disease-model-platform-and-us-operations 2026-01-13T21:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/oramed-and-lifeward-announce-strategic-merger-creating-diversified-biomedical-platform 2026-01-13T21:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/soley-therapeutics-raises-200m-series-c-to-advance-cell-stress-sensing-platform-and-aml-drug-candidate 2026-01-13T20:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/bd-invests-110-million-in-nebraska-manufacturing-to-support-biologic-drug-supply-chain 2026-01-13T20:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-modella-ai-in-first-major-pharma-ai-deal-to-accelerate-oncology-drug-development 2026-01-13T20:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-oxford-and-serum-institute-create-world-s-largest-rift-valley-fever-vaccine-reserve-amid-west-africa-outbreak 2026-01-13T20:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-reports-landmark-year-with-five-pivotal-drug-approvals-accelerates-growth-strategy-across-oncology-and-cardiovascular-medicine 2026-01-13T20:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-mifepristone-oversight-found-to-be-science-based-in-comprehensive-document-review 2026-01-13T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-ipsen-s-ipn60340-for-first-line-acute-myeloid-leukemia 2026-01-13T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/cedars-sinai-develops-ai-powered-platform-to-predict-drug-toxicity-using-human-organoids 2026-01-13T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requests-removal-of-suicide-risk-warnings-from-glp-1-weight-loss-medications-following-comprehensive-safety-review 2026-01-13T20:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/gardp-and-debiopharm-partner-to-develop-novel-first-in-class-antibiotic-for-multidrug-resistant-gonorrhea 2026-01-13T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-candidate-evt0185-shows-promise-for-reversing-liver-fibrosis-in-preclinical-studies 2026-01-13T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/marea-therapeutics-reports-positive-phase-1-results-for-mar002-acromegaly-treatment 2026-01-13T16:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/european-patent-office-approves-iconovo-s-icopre-r-inhaler-patent-application-for-generic-ellipta-alternative 2026-01-13T16:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/applied-cells-and-immuneel-therapeutics-partner-to-develop-affordable-car-t-therapies-for-india-and-global-markets 2026-01-13T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tgf-b1-inhibitor-linavonkibart-shows-promise-in-overcoming-immune-checkpoint-resistance 2026-01-13T16:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-compound-shows-promise-for-myotonic-dystrophy-type-1-treatment-advances-to-clinical-trial 2026-01-13T16:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-submits-fifth-us-product-for-fda-review-as-bevacizumab-biosimilar-hlx04-receives-bla-acceptance 2026-01-13T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/xtl-biopharmaceuticals-acquires-85-of-neuronos-in-32-5m-deal-to-target-autism-therapeutics-market 2026-01-13T16:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/converge-bio-secures-25m-series-a-to-accelerate-ai-driven-drug-discovery-platform 2026-01-13T16:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-first-in-class-il-11-inhibitor-bi-765423-to-phase-ii-trial-for-idiopathic-pulmonary-fibrosis 2026-01-13T16:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-launches-billion-cell-atlas-to-accelerate-ai-driven-drug-discovery 2026-01-13T16:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-presents-new-depression-treatment-data-at-acnp-2026-meeting 2026-01-13T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rha-dynamic-volume-for-midface-contour-enhancement-in-adults 2026-01-13T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-reaches-50-enrollment-in-phase-iii-maveric-trial-for-recurrent-pericarditis 2026-01-13T16:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-publishes-phase-3-simufilam-results-in-alzheimer-s-disease-reveals-biomarker-screening-challenges 2026-01-13T16:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapeutics-poised-for-major-market-expansion-as-industry-addresses-infrastructure-challenges 2026-01-13T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-grant-to-hongene-biotech-for-patent-free-mrna-vaccine-components 2026-01-13T12:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-heartlung-s-ai-cvd-platform-for-comprehensive-opportunistic-screening-across-multiple-disease-domains 2026-01-13T08:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/lyfesci-acquires-clinically-media-to-integrate-patient-recruitment-into-end-to-end-clinical-trial-services 2026-01-13T08:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/travere-therapeutics-reports-record-filspari-sales-and-prepares-for-fsgs-approval-decision 2026-01-13T05:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-advances-escharex-phase-iii-trial-and-expands-manufacturing-capacity-ahead-of-key-2026-milestones 2026-01-13T05:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-secures-improved-teverelix-license-terms-and-reports-promising-phase-1-data-in-women 2026-01-13T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/hippocratic-ai-expands-life-sciences-operations-with-grove-ai-acquisition-and-strategic-leadership-appointments 2026-01-13T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-reportedly-in-32-billion-acquisition-talks-with-merck-as-big-pharma-m-a-activity-surges 2026-01-13T00:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/yoga-accelerates-opioid-withdrawal-recovery-by-4-4-times-in-clinical-trial 2026-01-12T21:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/avenue-biosciences-raises-5-7m-to-scale-high-throughput-protein-engineering-platform 2026-01-12T21:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/uae-becomes-second-country-globally-to-approve-dual-action-heart-failure-drug-inpefa 2026-01-12T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-outlines-2026-clinical-roadmap-for-obesity-drug-nimacimab-following-positive-phase-2a-results 2026-01-12T21:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurelis-reports-transformational-growth-with-valtoco-expansion-and-patent-extensions-through-2032 2026-01-12T21:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-advances-phase-2-atopic-dermatitis-trial-with-first-in-class-il-36-il-31-inhibitor-gx-03 2026-01-12T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-acquires-pan-amyloid-imaging-agents-from-attralus-to-advance-cardiac-amyloidosis-diagnosis 2026-01-12T21:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/humana-s-centerwell-pharmacy-partners-with-eli-lilly-to-expand-employer-based-access-to-obesity-medications 2026-01-12T21:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-accelerates-ibd-pipeline-with-six-proof-of-concept-readouts-expected-in-2026 2026-01-12T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/whole-genome-sequencing-algorithm-outperforms-standard-tests-for-predicting-parp-inhibitor-response 2026-01-12T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/mindmed-rebrands-as-definium-therapeutics-prepares-for-three-phase-3-psychedelic-therapy-readouts-in-2026 2026-01-12T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-s-ibtrozi-demonstrates-strong-commercial-performance-with-432-new-patients-in-first-six-months 2026-01-12T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-increases-stake-in-joint-venture-as-b7h3-targeting-radiopharmaceutical-betabart-advances-to-phase-i-trial 2026-01-12T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-partners-with-eisai-in-eur195-million-deal-to-expand-taletrectinib-global-reach-for-ros1-nsclc 2026-01-12T17:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/obi-pharma-and-tegmine-therapeutics-form-global-license-partnership-for-novel-glycan-targeting-adc 2026-01-12T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/precede-biosciences-raises-83-5m-to-scale-blood-based-precision-diagnostics-platform-for-next-generation-cancer-therapies 2026-01-12T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/vidac-pharma-secures-uspto-patent-for-novel-hexokinase-2-mitochondrial-interaction-modulators 2026-01-12T16:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-atara-biotherapeutics-rare-blood-cancer-therapy-despite-prior-internal-support 2026-01-12T16:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/france-expands-national-compassionate-access-for-agenus-botensilimab-balstilimab-combination-to-include-ovarian-cancer-and-soft-tissue-sarcomas 2026-01-12T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-advances-abcl635-to-phase-2-trial-for-non-hormonal-menopause-treatment 2026-01-12T16:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/b-flexion-life-sciences-acquires-majority-stake-in-radius-health-consolidating-ownership-of-tymlos-osteoporosis-treatment 2026-01-12T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/pacbio-partners-with-n-lorem-foundation-and-esperare-to-advance-personalized-aso-therapies-for-ultra-rare-genetic-diseases 2026-01-12T16:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/scineuro-and-novartis-strike-1-65-billion-alzheimer-s-partnership-for-blood-brain-barrier-technology 2026-01-12T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-chinese-biotech-s-radioligand-therapy-asset-in-50-million-deal 2026-01-12T16:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-commits-555-million-to-expand-u-s-manufacturing-capabilities-with-arizona-acquisition-and-illinois-facility-expansion 2026-01-12T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/outsee-secures-ps2-5m-seed-funding-and-partners-with-o2h-discovery-to-advance-ai-driven-drug-target-discovery 2026-01-12T16:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/kailera-therapeutics-initiates-global-phase-3-trials-for-dual-glp-1-gip-obesity-drug-following-strong-chinese-study-results 2026-01-12T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-reports-promising-phase-i-ii-data-for-gene-therapy-lx2020-in-rare-heart-disease 2026-01-12T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-5-6-billion-licensing-deal-for-novel-pd-1-vegf-bispecific-antibody-rc148 2026-01-12T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-expands-precision-oncology-partnerships-with-northwestern-medicine-and-nyu-langone-health 2026-01-12T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-reports-strong-2025-performance-and-outlines-ambitious-2026-pipeline-milestones 2026-01-12T16:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-novel-fascin-inhibitor-np-g2-044-for-pancreatic-cancer-treatment 2026-01-12T16:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-clearance-for-minimed-go-smart-mdi-system-with-abbott-s-instinct-sensor 2026-01-12T16:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/sebela-pharmaceuticals-submits-nda-for-tegoprazan-novel-p-cab-showing-superior-gerd-treatment-efficacy 2026-01-12T16:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-receives-fda-clearance-for-epetraborole-trial-in-mycobacterium-abscessus-lung-disease 2026-01-12T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/suvoda-advances-clinical-trial-technology-with-ai-integration-and-patient-centric-platform-following-greenphire-merger 2026-01-12T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-secures-exclusive-rights-to-synthetic-acth-analog-amp-110-in-158-million-deal 2026-01-12T12:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-trastuzumab-combination-shows-promise-in-her2-positive-ras-wild-type-colorectal-cancer 2026-01-12T12:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-tentative-approval-for-400mg-bosutinib-cancer-treatment 2026-01-12T12:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/fabentech-receives-first-ever-marketing-authorization-for-ricimed-revolutionary-ricin-poisoning-antidote 2026-01-12T12:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-prepares-fda-filing-for-first-ever-sleep-apnea-pill-following-successful-phase-3-trials 2026-01-12T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/oricell-therapeutics-raises-70m-series-c1-to-advance-gpc3-targeted-car-t-therapy-for-hepatocellular-carcinoma 2026-01-12T09:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/enginzyme-and-agc-develop-scalable-manufacturing-process-for-critical-mrna-vaccine-component 2026-01-12T09:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-develop-precision-immunotherapy-for-myelofibrosis-blood-cancer 2026-01-12T09:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/advicenne-secures-five-year-marketing-authorization-renewal-for-sibnayal-in-european-union 2026-01-12T09:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-receives-fda-approval-for-generic-everolimus-tablets-for-rare-neurological-disorder 2026-01-12T09:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-flexible-manufacturing-requirements-for-cell-and-gene-therapies-to-accelerate-innovation 2026-01-12T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/ubc-acquires-evidinno-outcomes-research-to-strengthen-real-world-evidence-and-health-economics-capabilities 2026-01-12T04:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-reports-positive-phase-iii-results-for-zemprocitinib-in-rheumatoid-arthritis 2026-01-12T04:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-reports-strong-ojemda-revenue-growth-and-expands-pipeline-through-mersana-acquisition 2026-01-12T01:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-launches-claude-for-healthcare-with-medical-record-integration-challenging-openai-in-healthcare-ai-market 2026-01-12T00:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-advances-multi-program-pipeline-with-phase-3-hypoparathyroidism-trial-and-novel-obesity-therapies 2026-01-12T00:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/alamar-biosciences-secures-50m-financing-to-advance-precision-proteomics-platform-for-early-disease-detection 2026-01-12T00:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-secures-fda-accelerated-approval-pathway-for-beam-302-and-plans-bla-submission-for-risto-cel-by-year-end-2026 2026-01-12T00:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-royalty-pharma-announce-500-million-funding-agreement-for-vitiligo-treatment-tev-408 2026-01-12T00:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/juvena-therapeutics-secures-33-5m-series-b-to-advance-ai-enabled-regenerative-biologics-pipeline 2026-01-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-s-bb-301-gene-therapy-shows-sustained-improvement-in-opmd-patients-at-24-month-follow-up 2026-01-11T17:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/carna-health-raises-8-million-to-scale-ai-driven-chronic-kidney-disease-screening-platform-globally 2026-01-11T12:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-blocks-edwards-lifesciences-jenavalve-acquisition-citing-innovation-harm-in-pre-commercial-tavr-market 2026-01-11T08:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/kinaset-therapeutics-secures-103-million-series-b-to-advance-novel-inhaled-jak-inhibitor-for-severe-asthma 2026-01-11T01:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/neratinib-shows-anti-atherosclerotic-effects-through-novel-ask1-pathway-in-preclinical-studies 2026-01-11T00:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/medicines360-licenses-novel-stillbirth-risk-assessment-technologies-from-cambridge-and-edinburgh-universities 2026-01-11T00:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-completes-phase-1-drug-drug-interaction-study-for-experimental-compound-azd0780-with-metformin 2026-01-10T20:54:38+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-initiates-phase-1-trial-for-new-skyclarys-tablet-formulation-to-improve-patient-access-in-friedreich-s-ataxia 2026-01-10T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/cg-oncology-accelerates-pivot-006-phase-3-timeline-for-bladder-cancer-treatment 2026-01-10T20:51:46+00:00 hourly 0.9 https://trial.medpath.com/news/etienna-bio-secures-exclusive-license-for-adipose-derived-regenerative-cell-platform-from-umass-chan-medical-school 2026-01-10T20:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/lucerastat-demonstrates-significant-efficacy-in-phase-3-trial-for-fabry-disease-treatment 2026-01-10T20:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-unveil-ai-platform-drugclip-that-accelerates-drug-screening-by-million-fold 2026-01-10T13:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-s-ocu410st-gene-therapy-shows-54-reduction-in-stargardt-disease-progression-in-phase-1-trial 2026-01-10T12:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-announces-ceo-succession-plan-as-jim-foster-retires-after-50-year-career 2026-01-10T09:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-secures-50-million-financing-to-advance-first-in-class-cancer-pipeline 2026-01-10T08:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/imfinzi-shows-survival-benefits-in-small-cell-lung-cancer-but-fails-cost-effectiveness-analysis 2026-01-10T08:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-bevacizumab-shows-superior-outcomes-compared-to-tace-in-intermediate-stage-hepatocellular-carcinoma 2026-01-10T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/mindwalk-identifies-universal-functional-constraint-across-influenza-viruses-using-ai-technology 2026-01-10T08:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-announces-1-billion-cell-therapy-manufacturing-plant-in-pennsylvania 2026-01-10T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/eikon-therapeutics-files-for-100-million-ipo-to-advance-late-stage-cancer-pipeline 2026-01-10T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/rolvedon-same-day-dosing-shows-promise-for-breast-cancer-patients-in-phase-1-trial 2026-01-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/amarin-reports-strong-q4-2025-performance-as-vascepa-vazkepa-franchise-positioned-to-benefit-from-emerging-triglyceride-therapies 2026-01-10T01:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-reports-strong-2025-performance-with-eur720m-revenue-and-advances-transcon-pipeline 2026-01-10T01:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-publishes-first-study-mapping-bk-polyomavirus-impact-on-kidney-transplant-recipients-quality-of-life 2026-01-10T00:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/haemonetics-acquires-vivasure-medical-for-eur100-million-to-expand-large-bore-vascular-closure-portfolio 2026-01-10T00:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-bayesian-statistical-methods-to-accelerate-clinical-trial-design 2026-01-10T00:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-secures-6-5-billion-houston-manufacturing-plant-with-major-tax-incentives 2026-01-09T23:51:56+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-secures-250m-financing-to-prepare-for-orca-t-commercial-launch-ahead-of-april-2026-fda-decision 2026-01-09T20:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/scancell-s-dna-immunotherapy-shows-74-progression-free-survival-in-advanced-melanoma-phase-2-trial 2026-01-09T20:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/marius-pharmaceuticals-initiates-post-marketing-study-of-testosterone-undecanoate-in-men-aged-65-80-with-hypogonadism 2026-01-09T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-and-definium-near-regulatory-milestones-as-psychedelics-field-approaches-commercial-reality 2026-01-09T20:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/diamyd-medical-s-type-1-diabetes-immunotherapy-receives-global-non-proprietary-name-retogatein 2026-01-09T20:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-initiates-first-in-human-trial-of-st-01156-novel-molecular-glue-degrader-targeting-rbm39 2026-01-09T20:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/bit-bio-secures-50-million-series-c-funding-to-advance-human-cell-programming-technology-for-drug-discovery 2026-01-09T20:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-s-tg4050-achieves-100-two-year-disease-free-survival-in-head-and-neck-cancer-phase-i-trial 2026-01-09T20:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-launches-phase-iii-trial-testing-lebrikizumab-for-nummular-eczema-treatment 2026-01-09T20:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-pembrolizumab-fails-to-improve-outcomes-in-hepatocellular-carcinoma-after-curative-treatment 2026-01-09T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-pennsylvania-biontech-and-oup-launch-50-million-life-sciences-venture-fund 2026-01-09T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-discontinues-mesothelin-targeting-adc-pf-08052666-amid-strategic-pipeline-restructuring 2026-01-09T20:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-s-tegoprubart-shows-promise-in-phase-2-kidney-transplant-trial-advances-to-phase-3-development 2026-01-09T19:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/anika-therapeutics-names-steve-griffin-ceo-as-company-focuses-on-hyaluronic-acid-pipeline 2026-01-09T19:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/cartesian-therapeutics-advances-car-t-therapy-pipeline-with-fda-approval-for-myositis-trial-and-positive-phase-3-progress 2026-01-09T19:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-therapeutics-secures-60-million-equity-line-of-credit-to-advance-multispecific-cancer-immunotherapy-pipeline 2026-01-09T19:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/sparc-restructures-operations-with-10m-cost-savings-target-while-advancing-oncology-and-immunology-pipeline 2026-01-09T19:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/bleichroeder-acquisition-corp-ii-completes-287-5m-ipo-targeting-healthcare-technology-disruption 2026-01-09T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-and-acepodia-expand-partnership-for-next-generation-dual-payload-bispecific-adcs 2026-01-09T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-car-t-cell-therapy-shows-promising-results-for-myasthenia-gravis-in-phase-2b-trial 2026-01-09T16:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/global-alzheimer-s-platform-foundation-expands-bio-hermes-studies-with-strategic-partnerships 2026-01-09T16:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/gc-therapeutics-advances-tfometm-platform-with-novel-cell-therapies-for-multiple-sclerosis-and-type-1-diabetes 2026-01-09T16:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-dyrupeg-biosimilar-receives-health-canada-approval-for-cancer-neutropenia-treatment 2026-01-09T16:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/inflarx-cuts-30-of-workforce-deprioritizes-covid-19-therapy-to-focus-on-immunology-pipeline 2026-01-09T16:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-partners-with-eli-lilly-to-integrate-tunelab-ai-platform-into-livedesign-software 2026-01-09T16:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/cytoreason-expands-ai-driven-drug-discovery-partnership-with-sanofi-in-16-million-multi-year-deal 2026-01-09T16:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/airnexis-therapeutics-secures-200m-series-a-to-advance-dual-pde3-4-inhibitor-for-copd-treatment 2026-01-09T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/enodia-therapeutics-secures-eur20-7m-seed-funding-to-advance-novel-protein-degradation-platform-targeting-sec61-translocon 2026-01-09T16:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/ping-an-biomedical-secures-90-million-in-strategic-investments-to-accelerate-biopharmaceutical-innovation 2026-01-09T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-advances-iopofosine-i-131-toward-european-approval-for-waldenstrom-s-macroglobulinemia 2026-01-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/newamsterdam-pharma-advances-obicetrapib-development-with-promising-alzheimer-s-biomarker-data-and-multiple-phase-3-trials 2026-01-09T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-reports-strong-brinsupri-launch-with-144-6m-first-quarter-revenue-advances-multiple-phase-3-programs 2026-01-09T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-reports-strong-commercial-launch-progress-for-vykat-xr-in-prader-willi-syndrome 2026-01-09T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-camurus-resubmitted-nda-for-oclaiz-acromegaly-treatment-with-june-2026-pdufa-date 2026-01-09T16:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-outlines-2026-strategic-priorities-with-focus-on-melanoma-franchise-expansion-and-pipeline-advancement 2026-01-09T15:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/a2-biotherapeutics-receives-fda-clearance-for-a2b543-car-t-therapy-with-il-12-booster-for-advanced-solid-tumors 2026-01-09T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-reports-strong-yutrepia-launch-with-148-3m-in-full-year-2025-sales-expands-clinical-pipeline 2026-01-09T15:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/huons-biopharma-s-hutox-becomes-seventh-botulinum-toxin-approved-in-china-following-nmpa-authorization 2026-01-09T15:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-achieves-complete-b-cell-depletion-in-non-human-primates-with-in-vivo-car-t-platform 2026-01-09T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-expands-leadership-and-research-partnerships-to-advance-live-tumor-immunotherapy-platform 2026-01-09T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/collegium-pharmaceutical-secures-980-million-credit-facility-and-authorizes-generic-nucynta-launch 2026-01-09T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-receives-fda-ind-clearance-for-phase-2b-trial-of-mh002-live-biotherapeutic-in-ulcerative-colitis 2026-01-09T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-advances-amx0318-as-long-acting-glp-1-receptor-antagonist-for-post-bariatric-hypoglycemia 2026-01-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/medilink-and-roche-expand-partnership-with-570-million-deal-for-b7h3-targeting-adc-yl201 2026-01-09T05:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/entrada-therapeutics-advances-rna-based-pipeline-with-first-ocular-candidate-for-usher-syndrome 2026-01-09T01:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-launches-first-commercial-integration-of-one-year-cgm-with-automated-insulin-delivery-system 2026-01-09T01:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/mit-engineers-develop-biodegradable-smart-pills-that-report-medication-intake-to-healthcare-providers 2026-01-09T01:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/osel-launches-first-ever-pivotal-trial-of-microbiome-based-cancer-therapy-mo-03-for-advanced-renal-cell-carcinoma 2026-01-09T01:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/acuitas-therapeutics-acquires-majority-stake-in-rna-technologies-therapeutics-to-advance-rna-lnp-therapeutics 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/one-genomics-partners-with-cira-foundation-to-advance-high-precision-crispr-technology-for-regenerative-medicine 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/enliven-therapeutics-reports-promising-phase-1b-results-for-elvn-001-in-treatment-resistant-chronic-myeloid-leukemia 2026-01-09T00:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-and-veeva-systems-expand-strategic-partnership-to-accelerate-rare-disease-drug-development 2026-01-09T00:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/tecregen-secures-eur11m-seed-funding-and-appoints-new-ceo-to-advance-thymus-regeneration-therapeutics 2026-01-09T00:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-class-non-opioid-journavx-for-acute-pain-marking-20-year-breakthrough 2026-01-09T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/ubc-researchers-achieve-breakthrough-in-stem-cell-derived-helper-t-cell-production-for-cancer-therapy 2026-01-09T00:58:05+00:00 hourly 0.9 https://trial.medpath.com/news/uc-san-diego-researchers-demonstrate-first-successful-personalized-cancer-treatment-based-on-tumor-dna 2026-01-09T00:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-names-rick-suarez-us-president-to-lead-50-billion-investment-strategy 2026-01-08T21:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-s-synaffix-partners-with-sidewinder-therapeutics-to-develop-next-generation-bispecific-adcs-for-solid-tumors 2026-01-08T21:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/santhera-secures-swiss-approval-for-agamree-as-nxera-expands-asia-pacific-access-for-duchenne-muscular-dystrophy-treatment 2026-01-08T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/acousia-therapeutics-completes-enrollment-in-phase-2-trial-testing-acou085-for-cisplatin-induced-hearing-loss 2026-01-08T21:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-partners-with-panther-to-advance-africa-cdc-led-mpox-treatment-trial 2026-01-08T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/alveus-therapeutics-emerges-with-160m-to-develop-next-generation-obesity-therapies 2026-01-08T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/abbelight-secures-series-b-funding-to-expand-super-resolution-microscopy-technology-for-drug-discovery-applications 2026-01-08T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/intent-biologics-receives-fda-fast-track-designation-for-first-in-class-exosome-therapy-for-diabetic-foot-ulcers 2026-01-08T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/renexxion-secures-sixth-u-s-patent-for-naronapride-trihydrate-formulation-targeting-multiple-gi-disorders 2026-01-08T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-advances-t-cell-engagers-to-phase-2-studies-for-autoimmune-diseases 2026-01-08T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-launches-phase-1-trial-of-agent-797-for-graft-versus-host-disease-prevention 2026-01-08T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-launches-phase-1-trial-of-oral-glp-1-glp-2-dual-agonist-rt-114-for-obesity-treatment 2026-01-08T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-platform-identifies-pancreatic-cancer-patient-subgroup-with-threefold-survival-improvement 2026-01-08T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/glycoera-appoints-petra-duda-as-chief-medical-officer-to-lead-precision-protein-degrader-pipeline 2026-01-08T21:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-reports-positive-preliminary-results-for-cannabinoid-based-cancer-pain-treatment 2026-01-08T21:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-combination-therapy-shows-superior-efficacy-in-first-of-kind-trial-for-psoriatic-arthritis-patients-with-obesity 2026-01-08T21:00:23+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-reports-positive-phase-1-safety-data-for-rna-editing-therapy-ax-0810-advances-pipeline-programs 2026-01-08T21:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-therapeutics-strengthens-leadership-team-with-new-chief-commercial-officer-and-board-restructuring 2026-01-08T21:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-initiates-two-phase-1-trials-expanding-oncology-pipeline-with-abbv-901-and-abbv-243 2026-01-08T21:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-partners-with-boltz-to-integrate-ai-models-into-drug-discovery-pipeline 2026-01-08T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/enyo-pharma-s-vonafexor-reverses-kidney-function-decline-in-phase-2-alport-syndrome-trial 2026-01-08T20:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/critics-ii-trial-identifies-optimal-preoperative-strategy-for-resectable-gastric-cancer 2026-01-08T20:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/varmx-and-rentschler-biopharma-expand-partnership-for-phase-iii-development-of-novel-coagulation-therapy-vmx-c001 2026-01-08T20:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/nautilus-biotechnology-launches-early-access-program-for-single-molecule-proteomics-platform-with-tau-proteoforms-assay 2026-01-08T20:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/engitix-secures-eur21-million-series-a-extension-to-advance-ecm-targeted-cancer-and-fibrosis-therapies 2026-01-08T20:59:17+00:00 hourly 0.9 https://trial.medpath.com/news/oncodesign-precision-medicine-and-ksilink-partner-to-screen-nanocyclix-r-library-for-cns-therapeutics 2026-01-08T20:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-alessa-s-enolen-for-localized-prostate-cancer-treatment 2026-01-08T20:57:56+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-submits-first-ever-targeted-therapy-for-guillain-barre-syndrome-to-european-regulators 2026-01-08T20:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/yale-study-reveals-gsk3b-inhibitors-as-promising-treatment-for-relapsed-b-cell-acute-lymphoblastic-leukemia 2026-01-08T20:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-secures-50-million-financing-to-advance-first-potential-treatment-for-sanfilippo-syndrome-type-b 2026-01-08T18:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-advances-masked-adc-varsetatug-masetecan-toward-registrational-trial-in-colorectal-cancer 2026-01-08T18:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/ardelyx-reports-strong-2025-performance-with-ibsrela-revenue-growing-73-and-launches-phase-3-trial-for-chronic-constipation 2026-01-08T18:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-secures-35-8m-funding-advances-masked-immuno-oncology-pipeline-with-key-development-milestones 2026-01-08T18:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/parabilis-medicines-secures-305-million-series-f-to-advance-first-in-class-b-catenin-inhibitor-zolucatetide 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/diagonal-therapeutics-secures-125m-series-b-to-advance-first-in-class-clustering-antibody-diag723-for-rare-genetic-diseases 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-advances-haduvio-development-with-fda-end-of-phase-2-meeting-and-phase-2b-trial-plans-for-chronic-cough-treatment 2026-01-08T18:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-therapeutics-advances-two-next-generation-adcs-into-clinical-trials-with-fda-ind-clearances 2026-01-08T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/climb-bio-advances-multi-drug-pipeline-with-phase-2-trial-initiation-and-2026-data-readouts-expected 2026-01-08T18:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/atsena-therapeutics-completes-phase-i-ii-dosing-for-xlrs-gene-therapy-advances-to-pivotal-trial 2026-01-08T18:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/fox-chase-cancer-center-becomes-first-nci-designated-center-to-implement-3d-genome-diagnostics-for-cancer-care 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-agrees-to-4-00-per-share-acquisition-by-kuva-labs-in-85-premium-deal 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/enara-bio-strengthens-dark-antigen-platform-with-expanded-boehringer-partnership-and-new-cmo-ahead-of-ena101-clinical-entry 2026-01-08T18:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/kahr-bio-s-dsp107-shows-promising-17-5-month-survival-in-advanced-colorectal-cancer-phase-2-trial 2026-01-08T18:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/alveus-therapeutics-raises-160-million-series-a-to-advance-novel-obesity-therapies 2026-01-08T18:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/lexeo-therapeutics-partners-with-johnson-johnson-to-advance-localized-cardiac-gene-therapy-using-impella-heart-pump-technology 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-advances-gene-therapy-for-stargardt-disease-with-first-patient-dosed-in-phase-1-2-expansion-trial 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/enanta-pharmaceuticals-advances-rsv-treatment-pipeline-and-expands-immunology-portfolio-with-three-novel-targets 2026-01-08T18:00:04+00:00 hourly 0.9 https://trial.medpath.com/news/enterobiotix-s-ebx-102-02-shows-promise-as-first-in-class-oral-microbiome-therapy-for-irritable-bowel-syndrome 2026-01-08T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/858-therapeutics-receives-fda-fast-track-designation-for-parg-inhibitor-etx-19477-in-brca-mutated-ovarian-cancer 2026-01-08T17:58:57+00:00 hourly 0.9 https://trial.medpath.com/news/bamf-health-and-henry-ford-health-partner-to-establish-comprehensive-theranostics-center-in-detroit 2026-01-08T17:58:48+00:00 hourly 0.9 https://trial.medpath.com/news/antin-infrastructure-partners-acquires-clinical-trial-equipment-leader-emsere-in-strategic-healthcare-move 2026-01-08T17:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/just-evotec-biologics-secures-gates-foundation-grant-for-ai-driven-monoclonal-antibody-optimization-to-expand-global-access 2026-01-08T13:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/storm-therapeutics-partners-with-alidabio-to-advance-first-in-class-rna-modifying-enzyme-inhibitor-stc-15 2026-01-08T13:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/epibiologics-raises-107m-series-b-to-advance-novel-egfr-targeting-bispecific-antibody-epi-326-into-clinical-trials 2026-01-08T13:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/krystal-biotech-to-present-phase-1-data-for-kb407-gene-therapy-in-cystic-fibrosis 2026-01-08T12:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/hansoh-pharmaceutical-s-aumolertinib-receives-eu-approval-for-advanced-nsclc-treatment 2026-01-08T12:59:29+00:00 hourly 0.9 https://trial.medpath.com/news/aboleris-pharma-advances-novel-anti-cd45rc-antibody-abo21009-to-patient-testing-in-rheumatoid-arthritis-phase-1-trial 2026-01-08T12:59:24+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-therapeutics-in-584-5-million-deal 2026-01-08T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-spine-secures-two-new-u-s-patents-strengthening-spinal-implant-innovation-portfolio 2026-01-08T12:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/tensive-reports-positive-pivotal-trial-results-for-regeneratm-bioresorbable-breast-reconstruction-device 2026-01-08T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/ligachem-bioscience-achieves-development-milestone-in-adc-platform-partnership-with-ono-pharmaceutical 2026-01-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/ametris-expands-digital-health-partnerships-with-major-pharmaceutical-companies 2026-01-08T10:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/pulmocide-terminates-phase-3-trial-of-inhaled-opelconazole-after-interim-analysis-shows-higher-mortality 2026-01-08T10:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/4moving-biotech-secures-fda-ind-clearance-for-first-in-class-intra-articular-glp-1-agonist-in-osteoarthritis 2026-01-08T09:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/neuralight-completes-paloma-study-demonstrating-superior-eye-movement-biomarkers-for-parkinson-s-disease-progression-tracking 2026-01-08T09:59:51+00:00 hourly 0.9 https://trial.medpath.com/news/spider-venom-derived-drug-ib409-enters-phase-1-clinical-trial-for-heart-attack-and-stroke-treatment 2026-01-08T09:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-ogsiveo-becomes-first-approved-desmoid-tumor-treatment-in-europe 2026-01-08T09:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-reports-promising-phase-1-results-for-novel-gipr-antagonist-at7687-in-obesity-treatment 2026-01-08T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ray-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-optogenetic-vision-therapies 2026-01-08T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bighat-biosciences-expands-lilly-partnership-to-develop-ai-powered-antibody-developability-models 2026-01-08T06:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-s-single-dose-oral-cholera-vaccine-panchol-demonstrates-safety-and-strong-immune-response-in-phase-1-trial 2026-01-08T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/mercy-health-system-joins-major-clinical-study-testing-multi-cancer-blood-screening-in-medicare-population 2026-01-08T04:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-initiates-phase-ib-trial-of-bbt002-bispecific-antibody-for-copd-treatment 2026-01-08T04:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/gland-pharma-receives-fda-approval-for-generic-extra-strength-pataday-eye-allergy-drops 2026-01-08T04:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/corsera-health-raises-80m-series-a-as-preventative-cardiovascular-sirna-therapy-enters-clinical-testing 2026-01-08T02:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-cognition-launches-real-world-study-for-zunveyl-as-alzheimer-s-drug-gains-commercial-traction 2026-01-08T02:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/prudentia-sciences-raises-20m-series-a-to-transform-life-sciences-due-diligence-with-ai-platform 2026-01-08T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bacterial-vesicles-boost-car-t-cell-therapy-effectiveness-against-solid-tumors 2026-01-08T02:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/pretrm-blood-test-reduces-preterm-birth-complications-in-large-randomized-trial 2026-01-08T02:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-s-gamifant-shows-promise-in-phase-2a-trial-for-interferon-gamma-driven-sepsis 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/ottimo-pharma-receives-fda-clearance-for-first-in-class-dual-pd-1-vegfr2-antibody-otp-01 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/deepseq-ai-secures-investment-from-zaka-vc-to-advance-ai-driven-protein-drug-discovery-platform 2026-01-08T02:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/arbele-s-arb1002-receives-fda-orphan-drug-designation-for-pancreatic-cancer-treatment 2026-01-08T02:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-acquires-lumabridge-to-establish-global-oncology-center-of-excellence 2026-01-08T02:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/elevatebio-reports-sixth-consecutive-year-of-revenue-growth-with-98-manufacturing-success-rate 2026-01-08T02:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-reduce-asthma-exacerbations-by-49-in-adolescents-with-obesity 2026-01-08T02:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-submits-ottava-robotic-surgical-system-to-fda-for-de-novo-classification 2026-01-08T02:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-initiates-phase-3-trial-for-vp-102-in-common-warts-treatment 2026-01-08T02:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/varsity-healthcare-partners-invests-in-trialbee-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/trialbee-secures-majority-investment-from-varsity-healthcare-partners-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-companies-seek-direct-deals-with-trump-administration-to-avoid-pricing-penalties 2026-01-08T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/volastra-therapeutics-expands-kif18a-inhibitor-program-following-positive-clinical-data 2026-01-08T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/ovation-science-secures-canadian-patent-for-enhanced-cannabinoid-transdermal-delivery-technology 2026-01-08T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-svn-15-matches-prozac-efficacy-in-depression-model-targets-dual-serotonin-dopamine-pathway 2026-01-08T02:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/lift-biosciences-appoints-new-ceo-as-company-prepares-for-phase-1-trial-of-novel-neutrophil-based-cancer-immunotherapy 2026-01-08T02:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/luminate-secures-21-million-series-a-to-advance-home-based-cancer-treatment-technology 2026-01-08T02:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-s-mrt-8102-demonstrates-85-reduction-in-cardiovascular-inflammation-marker-in-phase-1-trial 2026-01-08T02:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-secures-76-million-series-b-to-advance-first-in-class-anti-fibrotic-pipeline 2026-01-08T02:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/inimmune-launches-pivotal-phase-2-trial-of-ini-2004-for-allergic-rhinitis-treatment 2026-01-08T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/curium-receives-chinese-regulatory-approval-to-begin-phase-3-trial-of-177lu-psma-i-t-for-metastatic-prostate-cancer 2026-01-08T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/adicet-bio-advances-gamma-delta-t-cell-therapy-pipeline-with-fda-alignment-and-2026-milestones 2026-01-08T02:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-rebrands-as-kyntra-bio-advances-cd46-targeting-adc-and-roxadustat-programs 2026-01-08T02:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-grant-orphan-drug-designation-to-cpi-008-for-pancreatic-cancer-surgical-imaging 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/realta-life-sciences-appoints-biotech-veteran-jonathan-rigby-to-board-as-company-advances-inflammation-targeting-pipeline 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-completes-phase-3-enrollment-for-multiple-sclerosis-drug-reports-positive-progressive-ms-data 2026-01-08T01:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-and-unravel-biosciences-partner-to-develop-first-in-class-remyelination-therapy-for-multiple-sclerosis 2026-01-08T01:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/headlamp-health-launches-lumos-ai-platform-to-transform-neuroscience-drug-development 2026-01-08T01:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-phase-3-kandlelit-007-trial-for-calderasib-keytruda-qlex-combination-in-kras-g12c-mutant-lung-cancer 2026-01-08T01:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-helix-in-multi-year-precision-medicine-collaboration-to-accelerate-drug-development 2026-01-08T01:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-comp360-psilocybin-ind-application-for-ptsd-treatment-as-compass-pathways-advances-late-stage-clinical-development 2026-01-08T01:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-secures-100-million-series-f-to-advance-asp-1929-toward-u-s-approval 2026-01-08T01:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-to-submit-snda-for-at-home-use-of-igalmi-in-agitation-treatment 2026-01-08T01:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-and-10x-genomics-launch-immunescape-program-to-decode-transplant-rejection-using-multiomics-technology 2026-01-08T01:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-partners-with-woda-to-expand-global-access-to-revuforj-through-multi-regional-managed-access-program 2026-01-08T01:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/silybin-carvedilol-combination-shows-synergistic-effects-against-liver-fibrosis-in-preclinical-studies 2026-01-08T01:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-acquires-entomon-to-strengthen-venom-immunotherapy-supply-chain 2026-01-08T01:55:41+00:00 hourly 0.9 https://trial.medpath.com/news/scenic-biotech-partners-with-ono-pharmaceutical-to-advance-novel-target-discovery-using-cell-seq-platform 2026-01-08T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-bepirovirsen-achieves-breakthrough-functional-cure-rates-in-phase-iii-chronic-hepatitis-b-trials 2026-01-08T01:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/neurosterix-initiates-phase-1-trial-of-ntx-253-novel-m4-receptor-modulator-for-schizophrenia-treatment 2026-01-08T01:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-experimental-hepatitis-b-drug-bepirovirsen-achieves-functional-cure-in-pivotal-studies 2026-01-08T01:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/jjp-biologics-reports-positive-phase-i-results-for-first-in-class-anti-cd89-antibody-jjp-1212 2026-01-08T01:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/merck-pursues-acquisition-of-cancer-drug-developer-revolution-medicines 2026-01-08T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/cvrx-launches-benefit-hf-trial-to-evaluate-barostim-therapy-in-expanded-heart-failure-population 2026-01-08T01:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-receives-fda-clearance-for-novel-btk-protein-degrader-apg-3288-in-b-cell-malignancies 2026-01-08T01:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/arcutis-projects-455-470m-zoryve-revenue-for-2026-as-dermatology-portfolio-expands 2026-01-08T01:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-sovleplenib-meets-primary-endpoint-in-phase-iii-trial-for-warm-autoimmune-hemolytic-anemia 2026-01-08T01:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/healthbiome-achieves-dual-regulatory-approval-for-akkermansia-based-muscle-health-ingredient 2026-01-08T01:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-sues-major-covid-19-vaccine-makers-over-alleged-mrna-technology-patent-infringement 2026-01-08T01:44:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-expands-genetic-medicine-portfolio-through-strategic-sirna-and-ai-partnerships 2026-01-08T01:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/picard-medical-launches-fda-cleared-connector-covers-for-syncardia-total-artificial-heart 2026-01-08T01:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/nucana-appoints-theresa-bruce-as-coo-to-advance-cancer-drug-pipeline 2026-01-08T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/dem-biopharma-to-present-first-in-class-adc-dem301-for-gastrointestinal-cancers-at-asco-gi-2026 2026-01-08T01:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-parkinson-s-therapies-advance-to-late-stage-clinical-trials 2026-01-08T01:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/instil-bio-terminates-licensing-agreement-and-discontinues-lead-cancer-drug-development 2026-01-08T01:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/exvade-bioscience-enrolls-first-patients-in-revolutionary-glioblastoma-trial-using-fda-breakthrough-tumor-monorail-device 2026-01-08T01:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/sparrow-pharmaceuticals-initiates-phase-2b-trial-of-clofutriben-for-difficult-to-control-type-2-diabetes 2026-01-08T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/mdxhealth-partners-with-oxford-to-validate-genomic-prostate-score-in-landmark-protect-trial 2026-01-08T01:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cuts-childhood-vaccine-schedule-from-17-to-11-diseases-impacting-major-vaccine-manufacturers 2026-01-08T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/novoron-bioscience-secures-2-5m-nih-grant-to-advance-human-brain-organoid-platform-for-alzheimer-s-drug-discovery 2026-01-08T01:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/legacy-healthcare-receives-fda-clearance-to-advance-botanical-drug-cinainu-into-phase-3-trial-for-alopecia-areata 2026-01-08T01:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/vivavision-biotech-receives-fda-approval-for-streamlined-vvn461hd-development-path-in-non-infectious-anterior-uveitis 2026-01-08T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/baird-medical-expands-global-microwave-ablation-technology-footprint-with-new-market-launches 2026-01-07T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/alloy-therapeutics-names-christian-cobaugh-ceo-of-genetic-medicines-division-to-advance-anticlastic-rna-platform 2026-01-07T09:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-gene-silencing-drugs-show-promise-in-early-obesity-studies-enhancing-weight-loss-when-combined-with-zepbound 2026-01-07T09:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/seres-therapeutics-publishes-mechanism-data-for-vowst-in-nature-medicine-validates-live-biotherapeutics-platform 2026-01-07T09:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/three-biotech-companies-secure-international-funding-for-next-generation-genetic-medicine-platform 2026-01-07T09:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-up-to-840-million-to-advance-acute-leukemia-pipeline 2026-01-07T09:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-secures-patent-license-for-obesity-drug-ct-996-in-100-million-deal-with-structure-therapeutics 2026-01-07T09:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/3t-biosciences-strengthens-leadership-with-key-appointments-to-advance-solid-tumor-immunotherapy-pipeline 2026-01-07T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/kincell-bio-appoints-industry-veteran-larry-pitcher-as-ceo-to-drive-cell-therapy-manufacturing-expansion 2026-01-07T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/aclaris-therapeutics-reports-positive-phase-1a-results-for-bispecific-antibody-ati-052-accelerating-development-timeline 2026-01-07T09:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/ibex-medical-analytics-expands-ai-powered-pathology-platform-to-support-early-stage-drug-development 2026-01-07T09:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/pridcor-therapeutics-advances-long-covid-treatment-with-peer-reviewed-publication-and-fda-ind-exemption-for-phase-2-shield-study 2026-01-07T09:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/bactolife-raises-eur30-million-series-b-to-commercialize-gut-health-binding-proteins-technology 2026-01-07T09:28:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-maviret-as-first-eight-week-treatment-for-acute-hepatitis-c 2026-01-07T09:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-skin-derived-paste-shows-promise-for-breast-reconstruction-after-cancer-surgery 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-s-dna-therapy-eg110a-maintains-88-reduction-in-neurogenic-bladder-incontinence-at-24-weeks 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-announces-ceo-succession-as-lisa-graver-takes-leadership-of-biosimilar-company 2026-01-07T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-nipocalimab-achieves-first-positive-phase-2-results-for-systemic-lupus-erythematosus-treatment 2026-01-07T09:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-s-gene-therapy-gpx-002-shows-promise-in-type-2-diabetes-animal-studies 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-advances-first-fda-approved-mitochondrial-therapy-forzinity-for-barth-syndrome 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomendics-advances-first-in-class-therapy-for-epidermolysis-bullosa-simplex-with-tames-02-trial 2026-01-07T09:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-advances-azenosertib-toward-potential-accelerated-approval-with-key-2026-milestones-in-ovarian-cancer 2026-01-07T09:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-strengthens-leadership-team-with-blueprint-medicines-veterans-as-dmr-001-advances-toward-clinical-trials 2026-01-07T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-partners-with-onconano-medicine-in-300m-drug-delivery-collaboration-for-cancer-therapeutics 2026-01-07T09:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/vividion-s-wrn-inhibitor-vvd-214-shows-promise-for-msi-high-cancers-in-journal-of-medicinal-chemistry-publication 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-and-astrazeneca-partner-to-deploy-ai-foundation-model-for-precision-oncology-development 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/regentis-gelrinc-demonstrates-near-complete-cartilage-repair-in-24-month-phase-ii-study-using-quantitative-mocart-assessment 2026-01-07T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-initiates-phase-2-trial-of-praliciguat-for-rare-kidney-disease-fsgs 2026-01-07T09:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-study-reveals-one-third-of-clinical-trial-procedures-are-non-essential-proposes-streamlined-data-collection-framework 2026-01-07T09:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-venous-stent-for-deep-venous-disease-in-ivc-and-iliofemoral-veins 2026-01-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/loqus23-advances-first-in-class-oral-drug-lqt-23-for-huntington-s-disease-treatment 2026-01-07T09:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-s-northstar-select-liquid-biopsy-selected-for-major-japanese-lung-cancer-resistance-study 2026-01-07T09:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-acquires-dark-blue-therapeutics-for-840-million-to-advance-aml-treatment 2026-01-07T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-italy-consortium-launches-ps3m-study-to-define-true-remission-in-inflammatory-arthritis 2026-01-07T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/variant-bio-launches-world-s-first-agentic-ai-platform-for-genomic-drug-discovery 2026-01-07T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-initiates-phase-1-trial-of-novel-mrna-hiv-vaccine-targeting-broadly-neutralizing-antibodies 2026-01-07T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/nanomosaic-appoints-dr-anne-marie-morse-to-lead-clinical-advisory-board-for-ultra-sensitive-diagnostic-platform 2026-01-07T09:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/biosplice-submits-first-potential-disease-modifying-osteoarthritis-drug-to-fda 2026-01-07T09:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/aclarion-advances-clarity-trial-enrollment-with-northwestern-medicine-and-scripps-health-participation 2026-01-07T09:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-s-zumilokibart-shows-promising-results-in-phase-1b-asthma-trial-with-durable-biomarker-suppression 2026-01-07T09:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/cyclerion-therapeutics-partners-with-medsteer-to-advance-cyc-126-for-treatment-resistant-depression 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/leon-s-fr-jet-technology-enables-high-concentration-mrna-lnp-manufacturing-with-enhanced-in-vivo-activity 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-initiates-european-enrollment-for-fortify-trial-testing-orticumab-in-post-heart-attack-inflammation 2026-01-07T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/hummingbird-bioscience-doses-first-patient-in-phase-i-trial-of-her3-targeted-adc-hmbd-501 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/acesion-pharma-initiates-phase-2-trial-of-first-in-class-sk-ion-channel-inhibitor-ap31969-for-atrial-fibrillation 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/ikarovec-secures-exclusive-option-for-vectorbuilder-s-novel-aav-capsid-technology-in-1b-deal-for-amd-gene-therapy 2026-01-07T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-expands-global-clinical-trial-network-through-strategic-partnerships-with-opis-and-medicover 2026-01-07T06:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-expands-ultrasensitive-pathlight-mrd-test-to-colorectal-cancer-following-strong-citcca-study-results 2026-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/waters-corporation-shareholders-approve-17-5-billion-merger-with-bd-biosciences-transaction-set-to-close-february-2026 2026-01-06T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-azstarys-for-adhd-treatment-offering-first-dual-mechanism-therapy-for-23-million-affected-patients 2026-01-06T10:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-set-to-release-phase-2-results-for-bmb-101-in-drug-resistant-epilepsy 2026-01-06T10:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-first-human-dosing-milestone-for-novel-cns-inhalation-therapy 2026-01-06T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/gut-bacteria-derived-molecule-doubles-lung-cancer-immunotherapy-response-in-preclinical-study 2026-01-06T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/sisram-medical-s-daxxify-clears-final-regulatory-hurdle-for-china-market-launch 2026-01-06T03:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/alumis-to-report-phase-3-onward-topline-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis 2026-01-06T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapy-gains-momentum-with-four-new-clinical-programs-entering-phase-1-studies 2026-01-06T00:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-raises-700-million-to-advance-rnai-therapeutics-pipeline 2026-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indiana-attorney-general-sues-eli-lilly-over-alleged-insulin-price-manipulation 2026-01-05T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/decipher-genomic-classifier-shows-promise-for-predicting-prostate-cancer-treatment-outcomes 2026-01-05T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-reports-strong-q4-revenue-growth-of-28-driven-by-jakafi-and-opzelura-performance 2026-01-05T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-reports-promising-early-results-for-olvi-vec-in-advanced-lung-cancer-trials 2026-01-05T20:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-developed-silica-nanoparticles-transform-cold-tumors-to-enhance-immunotherapy-response 2026-01-05T20:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/halozyme-expands-enhanze-technology-through-strategic-partnerships-with-takeda-and-skye-bioscience 2026-01-05T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-and-neurocare-group-partner-to-create-nationwide-neuroplastic-therapy-network-for-depression-and-ptsd 2026-01-05T17:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-nmra-511-shows-clinically-meaningful-results-in-phase-1b-alzheimer-s-agitation-study 2026-01-05T17:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-names-new-ceo-as-vopimetostat-advances-to-pivotal-studies 2026-01-05T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-oncology-publishes-promising-data-on-ccr8-targeting-antibody-tagmokitug-for-solid-tumors 2026-01-05T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-analysis-identifies-two-new-multiple-sclerosis-subtypes-advancing-precision-medicine-approaches 2026-01-05T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/major-leucovorin-autism-study-retracted-due-to-data-issues-as-largest-trial-approaches-2026-results 2026-01-05T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/multi-antigen-t-cell-therapy-shows-84-6-disease-control-rate-in-pancreatic-cancer-phase-1-2-trial 2026-01-05T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-ceo-to-advance-neuropathic-corneal-pain-treatment 2026-01-05T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-publishes-pivotal-vykat-xr-study-results-in-leading-endocrinology-journal 2026-01-05T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-launches-low-cost-insulin-biosimilar-and-ustekinumab-alternative-in-us-market 2026-01-05T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-therapeutics-outlines-2026-pipeline-strategy-with-multiple-clinical-readouts-expected 2026-01-05T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-therapeutics-advances-optogenetic-therapy-with-rolling-bla-submission-and-expansion-plans 2026-01-05T17:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-strengthens-leadership-team-with-experienced-oncology-executives 2026-01-05T17:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/nanjing-delova-s-qp-6211-achieves-primary-endpoints-in-phase-3-trials-for-postoperative-pain-management 2026-01-05T17:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/bd-achieves-first-prophylactic-hernia-prevention-case-in-europe-with-phasix-mesh-as-prevent-trial-nears-completion 2026-01-05T17:19:37+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-anxiety-medications-advance-toward-2026-fda-review-marking-first-major-breakthrough-in-over-a-decade 2026-01-05T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-advances-rhb-102-for-glp-1-therapy-side-effects-as-market-faces-35-billion-loss-risk 2026-01-05T16:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/angitia-biopharmaceuticals-completes-enrollment-in-phase-2-trial-of-dual-target-osteoporosis-therapy-aga2118 2026-01-05T16:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-and-fast-track-designations-to-protara-s-tara-002-for-pediatric-lymphatic-malformations 2026-01-05T16:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-secures-conditional-approval-pathway-for-hydronidone-in-china-following-successful-phase-3-trial 2026-01-05T16:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/maplight-therapeutics-receives-fda-fast-track-designation-for-alzheimer-s-disease-psychosis-treatment 2026-01-05T16:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-reveals-1221-precision-medicine-deals-worth-billions-since-2019 2026-01-05T16:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/stimlabs-launches-first-fda-cleared-human-umbilical-cord-particulate-device-for-wound-management 2026-01-05T16:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/synusight-abli-therapeutics-and-xingimaging-partner-to-advance-alpha-synuclein-pet-imaging-in-parkinson-s-disease-trials 2026-01-05T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/metavia-s-da-1726-demonstrates-9-1-weight-loss-and-significant-metabolic-benefits-in-phase-1b-obesity-trial 2026-01-05T16:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-pergolide-tablets-for-equine-cushing-disease-treatment 2026-01-05T16:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-advances-three-monoclonal-antibody-programs-for-autoimmune-diseases-with-phase-1-data-expected-in-2026 2026-01-05T13:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-announces-leadership-transition-as-karen-massey-set-to-replace-tim-van-hauwermeiren-as-ceo 2026-01-05T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-multiple-bispecific-antibody-programs-with-key-biliary-tract-cancer-data-expected-q1-2026 2026-01-05T13:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/oral-htt-lowering-drug-branaplam-shows-promise-but-halted-due-to-peripheral-neuropathy-in-phase-2-huntington-s-disease-trial 2026-01-05T13:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/megestrol-acetate-shows-dual-benefits-in-er-positive-breast-cancer-treatment 2026-01-05T13:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/earendil-labs-partners-with-sanofi-in-2-56-billion-ai-driven-bispecific-antibody-collaboration-for-autoimmune-diseases 2026-01-05T13:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/alcanza-clinical-research-expands-network-through-strategic-acquisition-of-tampa-bay-medical-research 2026-01-05T12:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/scinopharm-becomes-first-taiwan-company-to-win-fda-approval-for-complex-multiple-sclerosis-treatment 2026-01-05T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-plus-pembrolizumab-shows-24-response-rate-in-recurrent-ovarian-cancer 2026-01-05T08:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-develops-ai-platform-for-b-cell-reactive-cancer-vaccines-plans-2027-clinical-trials 2026-01-05T08:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-receives-fda-clearance-for-first-in-class-crispr-gene-therapy-trial-in-tgfbi-corneal-dystrophy 2026-01-05T08:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-advance-degrader-antibody-conjugate-platform 2026-01-05T06:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-rejuvenating-aging-intestines-in-preclinical-study 2026-01-05T06:39:03+00:00 hourly 0.9